Protocol #: 13-559 
Version Date:  December 16, 2016  
 
Local Protocol #: 13-559 
 
TITLE:   A Phase [ADDRESS_429415] Carcinoma  
 
Coordinating Center:    Dana -Farber Cancer Institute  
 *Principal Investigator  (PI): Erica L. Mayer, MD, MPH  
 Breast Oncology Center  
 Dana -Farber Cancer Institute  
  
  
   
   
 
 
 Investigators: 
 
 
  
 
 
 
 
  
 
 
 
 
 
  
  
 
 
 
  
 
 

Protocol #: 13-559 
Version Date:   December 16, 2016  
Quality of Life Analysis: 
 
  
  
 
 
   
Statistician:  
 William Barry , PhD   
 Department of Biostatistics and Computational Biology 
 Dana -Farber Cancer Institute  
  
  
   
 
Project Manager:  
  
   
  
  
 
  
   
 
Study Coordinator:  
 DFCI Study Coordinator 
 Dana -Farber Cancer Institute  
 Breast Oncology  
 [ADDRESS_429416].  [LOCATION_011], MA [ZIP_CODE] 
2 
 

Protocol #: 13-559 
Version Date:   December 16, 2016  
  
  
Responsible Research Nurse:    
   
   
  
  
   
 
Industry ([COMPANY_007]) -Supplied Agent:  Palbociclib  
Other Agent(s):  Aromatase inhibitor (letrozole, anastrozole, or exemestane), supplier:  commercial . Tamoxifen, supplier: commercial.  
 IND #:  119965 IND Sponsor:   Erica Mayer , MD , MPH    
 
Protocol Type / Version # / Version Date:  Sponsor Amendment 12 / Protocol  Version11 /  December 16 , 2016 
  
3 
 

Protocol #: 13-559 
Version Date:   December 16, 2016  
SCHEMA  
 
Non-randomized phase II study  
N = 165; Cycle = 28 days  
 
 
 
Continuation of AI  
or tamoxifen 
+ 
Palbociclib  
   
 
Primary endpoint:  
Completion of 
therapy at 2 years  R
E
G
I
S
TRAT
I
O
N Patient 
Characteristics:  
 
• HR+ breast 
cancer  
• Tolerance of 
ongoing adjuvant 
AI or tamoxifen  
 
4 
 
Protocol #: 13-559 
Version Date:   December 16, [ADDRESS_429417] Cancer  ........................................................... 10 
2.2 Palbociclib Mechanism of Action  ......................................................................... 11 
2.3 Palbociclib Preclinical Data  .................................................................................. 11 
2.4 Palbociclib Pharmacokinetic (PK) data  ................................................................ 13 
2.5 Palbociclib Dose Rationale  ................................................................................... 14 
2.6 Palbociclib Clinical Data  ...................................................................................... 14 
2.7 Quality of Life Analysis  ........................................................................................ 19 
2.8 Rationale  ............................................................................................................... 19 
3. PARTICIPANT SELECTION  .......................................................................................... 20 
3.1 Eligibility Criteria  ................................................................................................. 20 
3.2 Exclusion Criteria .................................................................................................. 23 
3.3 Inclusion of Women and Minorities  ..................................................................... 24 
4. REGISTRATION PROCEDURES  ................................................................................... 24 
4.1 General Guidelines for DF/HCC and DF/PCC Institutions  .................................. 24 
4.2 Recruitment Procedures  ........................................................................................ 25 
4.3 Registration Process for DF/HCC and DF/PCC Institutions  ................................ 25 
4.4 General Guidelines for Other Investigative Sites .................................................. 26 
4.5 Registration Process for Other Investigative Sites  ................................................ 26 
5. TREATMENT PLAN  ....................................................................................................... 27 
5 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
5.1 Overall Study Design and Plan ............................................................................. 27 
5.2 Pre-Treatment Criteria  .......................................................................................... 28 
5.3 Agent Administration  ............................................................................................ 29 
5.4 General Concomitant Medication and Supportive Care Guidelines  ..................... 29 
5.5 Duration of Therapy  .............................................................................................. 31 
5.6 Duration of Follow Up .......................................................................................... 32 
5.7 Criteria for Removal from Study .......................................................................... 32 
6. DOSING DELAYS/DOSE MODIFICATIONS  ............................................................... 33 
6.1 Toxicity Management  ........................................................................................... 33 
6.2 Palbociclib Dose Modifications/Delays  ................................................................ 34 
7. ADVERSE EVENTS:  LIST AND REPORTING REQUIREMENTS  ........................... 41 
7.1 Expected Toxicities  ............................................................................................... 41 
7.2 Adve rse Event Characteristics  .............................................................................. 42 
7.3 Expedited Adverse Event Reporting  ..................................................................... 43 
7.4 Expedited Reporting to the Food and Drug Administration (FDA)  ..................... 44 
7.5 Expedited Reporting to [COMPANY_007]  ............................................................................... 44 
7.6 Expedited Reporting to Hospi[INVESTIGATOR_52453]  ............................................. 46 
7.7 Routine Adverse Event Reporting  ........................................................................ 46 
8. PHARMACEUTICAL INFORMATION ......................................................................... 46 
8.1 Palbociclib  ............................................................................................................. 46 
8.2 Letrozole  ............................................................................................................... 50 
8.3 Anastrozole  ........................................................................................................... 51 
8.4 Exemestane ........................................................................................................... 51 
8.5 Tamoxifen ............................................................................................................. 52 
9. BIOMARKER, CORRELATIVE, AND SPECIAL STUDIES  ........................................ 53 
9.1 Research Specimen Collection  .............................................................................. 53 
9.2 Quality of Life  ....................................................................................................... 54 
9.3 Drug Adherence  .................................................................................................... 54 
10. STUDY CALENDAR  ....................................................................................................... 54 
6 
 
Protocol #: 13-559 
Version Date:   December 16, [ADDRESS_429418]  ....................................................................................... 58 
12. DATA REPORTING / REGULATORY REQUIREMENTS  .......................................... 58 
12.1  Data Reporting ...................................................................................................... 58 
12.2  Data Safety Monitoring  ......................................................................................... 58 
12.3  Multicenter Guidelines  .......................................................................................... 59 
12.4  Collaborative Agreements Language  .................................................................... 59 
13. STATISTICAL CONSIDERATIONS .............................................................................. 59 
13.1  Study Design/Endpoints  ........................................................................................ 59 
13.2  Sample Size/Accrual Rate ..................................................................................... 60 
13.3  Analysis of Secondary Endpoint: Safety of Extended Duration Therapy with Palbociclib and Endocrine Therapy
 ............................................................................................................................... 61 
13.4  Reporting and Exclusions  ..................................................................................... 62 
13.5  Analysis of Q uality of Life Assessments  .............................................................. 62 
14. PUBLICATION PLAN  ..................................................................................................... 63 
15. REFERENCES .................................................................................................................. 64 
APPENDIX A: Easter n Cooperative Oncology Group (ECOG) Performance Status Criteria  .... 67 
APPENDIX B: CYP3A Inducers/Inhibitors and Information on Possibl e Drug Interactions  ...... 68 
APPENDIX C: Common Terminology Criteria for Adverse Events (version 4.0)  ...................... 70 
APPENDIX D: 13 -559 Study Participant Self -Administered Drug Diary  ................................... 71 
APPENDIX E: 13 -559 SPE CIMEN REQUISITION Form  ......................................................... 76 
APPENDIX F: List of Drugs Known to Predispose to Torsade de Pointes  ................................. 77 
APPENDIX G: Dana -Farber/Harvard Cancer Center Multi -Center Data and Safety Monitoring Plan 78 
7 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
1.0 INTRODUCTION  ........................................................................................................... 80 
1.1 Purpose  ................................................................................................................. 80 
1.2 Multi -Center Data and Safety Monitoring Plan Definitions  ........................... 80 
2.0 GENERAL ROLES AND RESPONSIBILITIES  ........................................................ 81 
2.1 DF/HCC Sponsor  ................................................................................................ 81 
2.2 Coordinati ng Center  ........................................................................................... 81 
2.3 DF/HCC Quality Assurance Office for Clinical Trials (QACT)  .................... 82 
2.4 Participating Institution  ..................................................................................... 82 
3.0 DF/HCC REQUIREMENTS FOR MULTI -CENTER PROTOCOLS  ..................... 83 
3.1 Protocol Distribution  .......................................................................................... 83 
3.2 Protocol Revisions and Closures  ........................................................................ 83 
3.3 Informed Consent Requirements ....................................................................... 83 
3.4 IRB Documentation  ............................................................................................ 84 
3.5 IRB Re -Approval  ................................................................................................ 84 
3.6 Participant Confidentiality and Authorization Statement  .............................. 84 
3.7 DF/HCC Multi- Center Protocol Registration Policy  ....................................... 85 
3.7.1  Participant Registration and Randomization  ................................................... 85 
3.7.2  Initiation of Therapy  ........................................................................................... 85 
3.7.3  Eligibility Exceptions  .......................................................................................... 85 
3.7.4  Verification of Registration, Dose Levels, and Arm Designation  ................... 85 
3.8 DF/HCC Protocol Case Number  ....................................................................... 85 
3.9 Protocol Deviations, Exceptions and Violations  ............................................... 85 
3.9.1  Definitions  ............................................................................................................ 86 
3.9.2  Reporting Procedures  ......................................................................................... 86 
3.10  Safety Assessments and Toxicity Monitoring  ................................................... 86 
3.10.1  Guidelines for Reporting Serious Adverse Events  ........................................... 87 
3.10.2  Guidelines for Processing IND Safety Reports  ................................................. 87 
3.11  Data Management  ............................................................................................... 87 
3.11.1  Data Forms Review  ............................................................................................. 87 
4.0 REQUISITIONING STUDY DRUG  ............................................................................. 88 
8 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
5.0 MONITORING: QUALITY CONTROL  ..................................................................... 88 
5.1 Ongoing Monitoring of Protocol Compliance  .................................................. 88 
5.2 Evaluation of Participating Institution Performance  ...................................... 89 
5.2.1  Monitoring Reports  ............................................................................................. 89 
5.2.2  Accrual of Eligible Participants:  ....................................................................... 89 
6.0 AUDITING: QUALITY ASSURANCE  ........................................................................ 90 
6.1 NCI Sponsored Trials  ......................................................................................... 90 
6.2 DF/HCC Sponsored Trials  ................................................................................. 90 
6.3 Participating Institution  ..................................................................................... 90 
6.4 DF/HCC Sponsor and Coordinating Center  .................................................... [ADDRESS_429419] Performance  ............................................................................... 90 
6.5.1  Corrective Actions  ............................................................................................... 90 
APPENDIX H: PFIZER SAE FAX COVER SHEET .................................................................. 92 
APPENDIX I: QOL Assessment  .................................................................................................. 93 
 
  
9 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
1. OBJECTIVES  
 
1.1 Study Design 
 
This is a single arm phase II pi[INVESTIGATOR_345859] 2 years of adjuvant 
endocrine therapy ( aromatase i nhibitor (AI) or tamoxifen) for patients with hormone receptor positive (HR+) breast cancer.   
 
1.2 Primary Objectives  
 
To evaluate the treatment discontinuation rate at 2 years for patients receiving combination therapy with endocrine therapy plus 
palbociclib. 
 
1.3 Secondary Objectives  
• To evaluate  treatment discontinuation rates in the subgroups of patients that receive AI and tamoxifen -based therapy  
 
• To describe the safety of extended duration therapy with endocrine therapy  plus palbociclib. 
1.4 Correlative Objectives  
• 
• 
2. BACKGROUND  
 
2.[ADDRESS_429420] Cancer 
 
Hormone receptor positive (HR+) breast cancer is the most commonly diagnosed subset of breast cancer, and affects thousands o f patients 
every year. Endocrine therapy is highly effective for this subset of breast cancer, and standard adjuvant management for  postmenopausal 
women with HR+ breast cancer includes adjuvant endocrine therapy for at least [ADDRESS_429421] cancer patients, and is an unmet medical need.  
 
10 
 

Protocol #: 13-559 
Version Date:   December 16, [ADDRESS_429422] HR+ breast cancer. One pathway of 
interest is the PI3K/mTOR pathway, and agents targeting this pathway, including everolimus, have demonstrated efficacy in com bination 
with either aromatase inhibitors or tamoxifen when treating endocrine -resistant metastatic HR+ breast cancer.1,2  Cell cycle inhibition is 
another target of choice, forming the biological motivation for the proposed trial.  
 
2.2 Palbociclib  Mechanism of Action  
 
Cell cycle inhibition is a target of choice for novel cancer therapeutics. PD-0332991 (palbociclib), an orally active pyridopyrimidine, is a 
potent first -in-class, highly selective reversible inhibitor of CDK 4 and CDK6 (IC 50 = 11 nM;  Ki = 2 nM) with a molecular weight of 
447.53.  Data from nonclinical studies indicate that palbociclib may have cytoreductive as well as cytostatic effects on tumor cells.  
 The compound prevents cellular DNA synthesis by [CONTACT_345896] l cycle from G1 into the S phase, as demonstrated 
both in laboratory models and in early clinical trials. CDK4 and CDK6 control G1 to S phase transit by [CONTACT_4639] D -type cyclins.
3-5 The 
CDK4/6/Cyclin D1 complex phosphorylates the retinoblastoma susceptibility ( RB1) gene product (Rb), releasing the E2F and DP 
transcription factors that drive expression of genes required for S -phase entry.[ADDRESS_429423].11,12 
 There is a strong link between the actions of estradiol and the G1- S phase transition, where the estradiol effector is the cyclin D1 -CDK4/[ADDRESS_429424] of ER+ breast cancer cells is accompanied by [CONTACT_345897] 
D1 expression23 while endocrine resistance is associated with persistent cyclin D1 expression and Rb phosphorylation.24 Consistent with 
the notion that the main function of cyclin D1 is to activate CDK4/6, its oncogenic activity is dependent on CDK4/6- associated kinase 
activity25 and CDK4/[ADDRESS_429425] effective in tumors with gene amplification and overexpression of cyclin D1,26-28 which is 
common in ER+ breast cancer.  For example,  palbociclib was most effective for ER+ breast cancer in a cell line panel,29 including those 
that exhibited anti -estrogen resistance. Genetic aberrations leading to hyperactivation of cyclin  D1-CDK4/6 is particularly common in ER+ 
breast cancer, consistent with its critical role in the tumorigenesis of this cancer subtype,29 making CDK4/6 inhibitors particularly 
attractive agents for ER+ breast cancer.   
 
2.[ADDRESS_429426] as well as potential secondary cytoreductive activity. Single agent  palbociclib has shown antiproliferative effects (selective G
[ADDRESS_429427]) on Rb -positive cancer cells in vitro  
11 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
and in vivo27 where palbociclib activity was associated with reduced Rb -phosphorylation and decreased expression of the  cell proliferation 
marker Ki67. Palbociclib showed no activity in Rb- negative tumor cell xenografts, consistent with CDK4/[ADDRESS_429428] cancer cell lines.  Results from these experiments indicate tha t 
those cell lines that are more sensitive to palbociclib (IC 50 < 150 nM) have low levels of CDKN2A (p16) and high levels of Rb1, while 
resistant cell lines show the opposite characteristics.  Of note for this study, ER+ breast cancer seems to be particularly appropriate for 
treatment with palbociclib; sensitive cell lines in this panel represent mostly the luminal ER+ subtype.29  
 The combination of palbociclib with tamoxifen has been tested in vitro in ER+ human breast cancer cell lines indicating a synergis tic 
interaction
[ADDRESS_429429] recent data from Julie Kan’s group in hormone resistant models (MCF7- CYP19) indicate a significant benefit from the combination 
of palbociclib and letrozole as well as palbociclib and fulvestrant over single agent letrozole and fulve strant  ([COMPANY_007], unpublished data).  
 Once daily oral administration of palbociclib  was well tolerated in rats at levels of 10 mg/kg/day for males and up to 200 mg/kg/day for 
females ( Sponsor Reference No. 12LJ025)  
30. 
 Palbociclib has been evaluated in safety pharmacology, genetic toxicity, reproductive and development (ferti lity and early embryonic 
development, embryofetal development), and repeat -dose toxicity studies of up to 15- weeks duration in the rat and dog.  Based on the 
nonclinical safety studies conducted with palbociclib, the primary palbociclib- related systemic to xicities were observed in 
hematolymphopoietic tissues (decreased cellularity, increased iron pi[INVESTIGATOR_2517], decreases in peripheral leukocytes and RBC parameters) and male reproductive organs (degeneration of seminiferous tubules, secondary epi[INVESTIGATOR_345860] a and increased intratubular cellular 
debris).  Partial to complete reversibility of toxicities was demonstrated following a [ADDRESS_429430] of palbociclib (i.e., cell cycle inhibition). (Fink et al, 2001; Arguello et al, 1998; Bartkova et al, 2003). Palbocic lib was also 
identified with the potential to cause QT prolongation, developmental effects, and aneugenicity.  Developmental effects that were considered adverse included a decrease in fetal body weights in rats and a low incidence of small phalanges on the forepaws i n rabbits. A 
12 
 
Protocol #: 13-559 
Version Date:   December 16, [ADDRESS_429431] formation has not been identified from the 
27-week rat toxicity study, based on the histological data (lens degener ation was noted microsc opi[INVESTIGATOR_897] ). Cataracts were identified from 
ophthalmic evaluations at the lower examined dose of 30 mg/kg/day in males but at no dose in females.  Further data from this toxicity study suggested a  correlation between altered glucose metabolism and the format ion of cataracts/lens 
degeneration. In dog toxicity studies (15- week and 39- week), no altered glucose levels or cataracts/lens degeneration have been observed 
(lack of lens degeneration not yet confirmed in the 39- week study; histopathology pending). Hyper glycemia and diabetes mellitus  are not 
considered to be identified clinical risks and are not considered to be adverse drug reactions (ADRs) of palbociclib.  
 
2.4 Palbociclib Pharmacokinetic (PK) data  
 
To date, pharmacokinetic data have been collected in 8 cli nical studies for a total of over 250 advanced cancer patients and 30 healthy 
volunteers (A5481001, A5481002, A5481003, A5481004, A5481008, A5481009, A5481010, and A5481011).  In the FIP trial (A5481001) the exposure (AUC
(0-10) and C max) increased in a dos e proportional manner over the dose range of 25 to 225 mg QD following 
palbociclib administration on Days 1 and 8 of Cycle  1, although some variability (low to moderate) around these doses was observed 
particularly at the 150 mg QD dose level.  Following r epeated daily dosing to Day 14 and Day 21 (assumed to be steady state), palbociclib 
was absorbed with a median T max of ~4  hours.  The mean palbociclib Vz/F was 3103 L, which is significantly greater than total body water 
(42 L), indicating that palbociclib extensively penetrates into peripheral tissues. Palbociclib was eliminated slowly; the mean elimination 
half-life (t ½) was 26.5 hours (ranged 15.8 to 36.2 hours) and the mean CL/F was 86.1 L/hour.  Palbociclib accumulated following repeated 
dosing with a median R ac of 2.4, which is consistent with the terminal half life. 
 A pi[INVESTIGATOR_345861] A5481001 and conducted in 12  patients following administration of either 125 mg or 
200 mg doses (the maximum tolerated dose/recommended phase 2 dose (RP2D) for the 3/1 and 2/1 schedules, respectively).  In general, no change in the rate of absorption was observed between the fed and fasted state (median T
max = 7 hours for both; range 3.5- 23 hours).  
However, higher exposures and peak concentrations were observed in the fed state compared to the fasted state (mean AUC (0-10): 370.5 vs 
290.5 ng•hr/mL, respectively; mean C max: 59.7 vs 42.8 ng/mL, respectively). B ased on these data, it can be concluded that since 
administration of palbociclib with a high fat meal may increase palbociclib exposure, patients should be fasted from 1 hour before to 2 hours after dosing (water is allowed), unless otherwise indicated in clinical protocols.  The effect of a non- fat meal on the PK of 
palbociclib has not been evaluated.  
13 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
 
Palbociclib is metabolized to multiple metabolites in a qualitatively similar manner in rat, dog and human liver microsomes.  In vitro, 
palbociclib is prim arily metabolized by [CONTACT_13439] P -450 (CYP) 3A4 enzymes.  An exploratory evaluation of the circulating metabolites 
for palbociclib  was conducted in plasma samples obtained from patients treated with palbociclib 200 mg QD (Schedule 2/1) in Study 
A5481001.  Preliminary assessment of the pooled plasma samples on Day 14 of Cycle 1 indicated that the glucuronide conjugate of 
palbociclib and the lactam of palbociclib (PF -05089326) were the main metabolites present in plasma.  Other metabolites observed were 
the glucuronide conjugates of hydroxylated palbociclib and the glucuronide conjugate of reduced palbociclib.  PF -05089326 was also 
observed in the circulation of rats following repeated daily oral administration of palbociclib at the dose levels of 50 and 100 m g/kg/day.  
Plasma protein binding of palbociclib and PF -05089326 is ~85% and 95%, respectively.  
 
2.5 Palbociclib Dose Rationale  
 
Palbociclib has been tested in a Phase 1 dose escalation Study (A5481001) in 74 patients with advanced cancer.  Two dosing sc hedule s 
were evaluated: Schedule 3/1 (3 weeks on treatment/1 week off treatment) and Schedule 2/1 (2 weeks on treatment/1 week off tr eatment). 
All dose limiting toxicities (DLTs) observed in this study were related to myelosuppression and mainly consisted of Gra de [ADDRESS_429432] 
common non- hematological adverse events included fatigue, anemia, diarrhea, constipation, vomiting and dyspnea , all with mild to 
moderate severity.  A greater proportion of patients on the 2/1 schedule had treatment -related TEAEs during and after Cycle 1 than 
patients on the 3/[ADDRESS_429433] to the 2  dosing 
schedules, both during and after Cycle 1.  One partial response (PR) was reported in a patient with testicular cancer. A tota l of 
13/37 patients treated with Schedule 3/1 evaluable for efficacy experienced stable disease (SD), including 6 patients with SD lasting 40 weeks or longer.  One of these patients was a woman with ER+ breast cancer who had previously received 7 lines of treatment f or her 
disease.  This patient remained on treatment for 80  weeks (7 cycles at 50 mg/d  and 13 cycles at 75 mg/d) and eventually discontinued 
treatment due to disease progression.  Based on the relatively improved safety profile of Schedule 3/1, and the efficacy results from this study, the Schedule 3/1 has been selected for further clinical  development and the RP2D for this schedule was determined to be 125 
mg/day.  This schedule and associated RP2D was further explored in combination with letrozole in the Phase I/II study in pati ents with 
advanced breast cancer described below.  
 
2.[ADDRESS_429434] cancer. Preliminary results were r eported at 
14 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
the American Society of Clinical Oncology (ASCO) [ADDRESS_429435] completed cycle 1.31 Palbociclib is given at 125 mg 
orally, days 1-  21 of a 28- day cycle.  Of the 28 women, 18 women are (64%) HR+/HER2 -, 2 (7%) are HR+/HER2+ and 8 (29%) HR -
/HER2 -negative. 90% had prior chemotherapy for metastatic disease (median 3 lines); 78% had prior hormonal therapy (median 2 lines).  
Grade 3/4 toxicities were limited to transient neutropenia (n=14; 50%) and thrombocytopenia (n=6; 21%).  One epi[INVESTIGATOR_345862] a patient with six previous chemotherapy regimens. All other toxicities were grade 1/2.  Treatment was interrupted 
in 7 (25%) and dose reduced in 13 (46%) pts for cytopenias; 27/28 patients discontinued study for disease progression. ( PR + SD > 6 
months) was as follows: 4 patients (23%) in HR+/HER2 -negative (n=18), 1 (50%) in HR+/HER2+ (n=2), 1 (13%) in HR -negative/HER2-
negative (n=8). In conclusion, therapy with palbociclib alone is well -tolerated, and demonstrates clinical benefit in patients with all 
subtypes of breast cancer and despi[INVESTIGATOR_196314] - and chemotherapy. Translational studies examining molecular 
predictors of response are in progress. 
 
2.6.2 Phase I/II trial of palbociclib in combination with letrozole  in advanced breast cancer  
 
A randomized, multicenter active -controlled Phase 1/2 Study (A5481003) was designed to assess the efficacy, safety and PK of letrozole 
2.5 mg QD (continuously) in combination with palbociclib 125 mg QD (schedule 3/1) versus single agent letrozole 2.5 mg QD (continuously) for the first -line treatment of ER+/ HER2 -negative advanced breast cancer in postmenopausal women.  Letrozole was 
selected as the active control based on its worldwide approval and use as standard of care for th e first- line hormonal treatment of 
postmenopausal women with ER+ advanced breast cancer.  
 Study A5481003 was comprised of a limited Phase [ADDRESS_429436] -line treatment of postmenopausal patients with ER+/HER2 -
negative advanced breast cancer.  The Phase 2 portion consisted of 2  parts.  In Part 1, patient selection was based only on ER/HER2 status.  
In Part 2, patients were prospectively selected also taking into account tumor CCND1 amplification and/or p16 loss.  A total of 177 patients were enrolled in the study. Twelve (12) were enrolled in the Phase 1 portion and 165 (66 and 99 in Part 1 and 2, respectively) were enrolled in the Phase 2 portion.  
 Results from the Phase 1 portion
32 indicated no PK interaction between palbociclib and letrozole  with mean AUC (0-24) of 2047 and 2021 
ng•hr/mL (n=12) for palbociclib in the absence and presence of letrozole, respectively, and 2027 and 1776 ng•hr/mL (n=11) for  letrozole 
in the absence and presence of palbociclib, respectively.  The RP2D was determined to be 125 mg QD on Schedule 3/1 (3 weeks 
continuous treatment followed by 1 week off treatment) in combination with letrozole 2.5 mg QD continuously.  PRs were reported for 3 
(33%) out of 9 patients with measurable disease (3 had bone -only disease). Another 5 patients (42%) had stable disease for ≥ 6 months and 
15 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
the clinical benefit rate (PR + SD ≥ 6 months) was 67%.  Eight (8) patients discontinued from the study due to disease progre ssion, 
including [ADDRESS_429437] been conducted. The results of the interim analyses showed consistent trend of clinically meaningful improvements in PFS (primary endpoint).  In the first interim analysis (Part 1; N=66), the median PFS for the palbociclib plus letrozole arm was 18.2 months versus 5.7 months for the letrozole alone arm (HR=0.35; 95% CI: 0.17, 0.72; p= 0.006).  
The second interim analysis (N=165) continued to demonstra te a statistically significant improvement in PFS (26.1 vs. 7.5 months, 
respectively; HR=0.37; 95% CI: 0.21, 0.63; p <0.001).
[ADDRESS_429438] frequently reported treatment -related adverse events included 
neutropenia, leukopenia, anemia, and fatigue. There were no cases of febrile neutropenia reported to date in this study.  Ove rall, 8 patients 
in the combination ar m were discontinued from the study treatment due to an adverse event, of which 5 were considered treatment -related 
(grade 3 neutropenia [n=4] and ischemic colitis) and 1 patient from the letrozole alone arm.  Additionally, the combination demonstrated 
antitumor activity which was consistent with the sensitivity of ER+ breast cancer observed in the preclinical models.  
 
Updated Safety Analysis of Study A5481003 
Cumulative incidences of t he most relevant all causality,  any Grade toxicities reported within the first year, and within the first 2 years of 
treatment with palbociclib were examined in 95 treated subjects enrolled in Study A5481003 with a data cutoff of 29 November 2013 (s ee 
table below ).  The cumulative incidence of neutropenia was identical (75.8%) within the first [ADDRESS_429439] to palbociclib’s myelosuppressive effects.  The cumulative incidences of other 
reported hematologic events were only slightly increased within the first [ADDRESS_429440] year of treatment only, including for Leucopenia (45.3% vs. 38.9%), Anemia (33.7 vs. 29.5%) and Thrombocytopenia (16.8% vs. 12.6%), yet the incidence was identical for Platelet count decreased (3.2% vs. 3.2%) and Hemoglobin decreased (3.2% vs. 3.2%). For gastrointestinal toxicities, the cumulative 
incidences were only marginally increased within the first [ADDRESS_429441] year only: Nausea 
(28.4% vs. 26.3%), Vomiting (14.7% vs. 13.7%), Diarrhea (22.1% vs. 18.9%), and Constipation (13.7% vs. 9.5%). Similarly, only small 
numeric al differences were observed in cumulative incidences within the first [ADDRESS_429442] to adverse events indicating Mucositis, such as Mucosal inflammation (7.4% vs. 7.4%) and Stomatitis ( 11.6% vs. 
7.4%), or with regard to infections, such as Nasopharyngitis (14.7% vs. 12.6%), Influenza (9.5% vs. 8.4%), Urinary tract infe ction (7.4% 
vs. 6.3%), and Influenza -like illness (5.3% vs. 5.3%). The corresponding incidence for hepatic (ALT increased , 6.3% vs. 5.3%; AST 
increased, 6.3% vs. 6.3%) or renal (Blood creatinine increased, 6.3% vs. 5.3%) laboratory parameters are similarly reassuring. The 
cumulative incidences of other commonly reported adverse events also remained relatively stable over tim e (ie, cumulative incidence 
16 
 
Protocol #: 13-559 
Version Date:   December 16, [ADDRESS_429443] year only), su ggesting that 
currently there is no evidence to suspect any specific cumulative or long -term toxicity a s a result of prolonged exposure to palbociclib: 
Fatigue (45.3% vs. 38.9%), Hot flush (21.1% vs. 21.1%), Alopecia (20.0% vs. 18.9%), Arthralgia (23.2% vs. 18.9%), and Astheni a (12.6% 
vs. 10.5%).  
 
Cumulative Incidence of TEAEs (All Causality) in the First Y ear of Treatment, the 
First 2 Years of Treatment, and in those Subjects Treated for More Than 2 Years of 
With Palbociclib on Study A5481003 (Descending Order of Frequency for Events 
Reported at Incidences >10 % in the First Year)  
Adverse Events  First Year  
N = [ADDRESS_429444] 2 
Years 
N = 95  > 2 Years  
N = 29 
Any adverse event  98.9 100.0  100.0  
Neutropenia  75.8 75.8 82.8 
Fatigue  38.9 45.3 55.2 
Leukopenia  38.9 45.3 51.7 
Anaemia  29.5 33.7 37.9 
Nausea  26.3 28.4 34.5 
Hot flush  21.1 21.1 20.7 
Alopecia  18.9 20.0 27.6 
Arthralgia  18.9 23.2 44.8 
Diarrhoea  18.9 22.1 44.8 
Decreased appetite  15.8 16.8 6.9 
Headache  13.7 13.7 24.1 
Vomiting  13.7 14.7 17.2 
Dyspnoea  12.6 16.8 13.8 
Nasopharyngitis  12.6 14.7 20.7 
Thrombocytopenia  12.6 16.8 20.7 
Asthenia  10.5 12.6 3.4 
17 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
Cumulative Incidence of TEAEs (All Causality) in the First Y ear of Treatment, the 
First 2 Years of Treatment, and in those Subjects Treated for More Than 2 Years of 
With Palbociclib on Study A5481003 (Descending Order of Frequency for Events 
Reported at Incidences >10 % in the First Year)  
Adverse Events  First Year  
N = [ADDRESS_429445] 2 
Years 
N = 95  > 2 Years  
N = [ADDRESS_429446] that tamoxifen and one of its primary active metabolites, 4- hydroxy- tamoxifen, are inducers of CYP3A4 enzymes. In clinical 
trials, co -administration of tamoxifen wi th letrozole and anastrozole (both CYP3A4 substrates) has resulted in decreased exposures (AUC) 
of each by 37% and 27%, respectively. Palbociclib is a CYP3A4 substrate and CYP3A4 is thought to be the primary route of the oxidative metabolism  of palbociclib. Thus, the co- administration of tamoxifen and palbociclib may lead to lower circulating levels of palbociclib and 
require an upward dose adjustment in palbociclib if these two compounds are used in conjunction. Additionally, time -dependent inhibition 
of CYP3A4 has been observed in preclinical studies of palbociclib, which could potentially impact the circulating steady- state levels of 
tamoxifen and its active metabolites.  
 A fixed -sequence [ADDRESS_429447] of steady -state levels of tamoxifen and its active 
metabolites on the pharmacokinetics of single dose palbociclib in healthy volunteers has been conducted to rule out a need for palbociclib dose-adjustments when used in conjunction with tamoxifen (A5481026). The preliminary data collected from [ADDRESS_429448] as a time -dependent inhibitor of CYP3A4, the pha rmacokinetics of a single 
oral dose of midazolam, a sensitive CYP3A4 substrate, with and without palbociclib dosed to steady- state was assessed in a healthy 
volunteer drug- drug interaction  study (A5481012). The results showed that geometric mean plasma mid azolam C
max and AUC inf values 
increased 1.37-  and 1.61 -fold, respectively, when a single oral dose of midazolam was co- administered with 125 mg dose of palbociclib 
18 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
following 6 daily 125 mg oral doses of palbociclib as compared to its administration alone. This indicates that palbociclib is a weak time-
dependent inhibitor of CYP3A4/5 following daily 125 mg dosing of palbociclib at steady- state.  
An in vivo  parallel cohort drug- drug interaction  assessment has been included in the Phase 3 PENELOPE B Study to assess the potential for 
palbociclib to alter the circulating steady -state levels of tamoxifen and its active metabolites.  
2.7 Quality of Life Analysis  
 Patient -reported outcomes (PRO) are an important part of new drug evaluation, and may play a role  in regulatory approval of novel agents 
in oncology.
33 PROs are evaluated through the use of questionnaires developed to assess topi[INVESTIGATOR_1102] a patient can report about his or her own 
health. This includes symptoms (i.e. nausea, fatigue, diarrhea), physical functioning (difficulty climbing stairs or fastening buttons), and mental health (i.e. anxiety, fear or worry).  
 Previous studies have demonstrated that patient and clinician reports of symptoms during cancer treatment provide discrepant but complimentary information. 
34-[ADDRESS_429449] mechanism for reporting toxicities in cancer research is clinician -only reporting 
using items from the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE). In a retrospective analysis of 14 randomized clinical trials whic h utilized simultaneous patient and clinician reporting , PRO measures improved the 
predictive accuracy of clinician CTCAE reporting.
37 In a prospective study including lung cancer patients PRO measurements of toxicities 
better reflected patients’ underlying state and functional status than clinician’s evaluation.35 
 In the current study, we will assess patient -reported quality of life via the European Organization for Research and Treatment of Cancer 
Quality of Life Questionnaire ( EORTC QLQ- C30) as well as fatigue via the Brief Fatigue Inventory (BFI) fatigue scale.  
 The EORTC QLQ C- 30 instrument was designed to measure health -related quality of life of patients with cancer. It consists of 30 items 
grouped into the following subscales: general physical symptoms, physical functioning, fatigue/malaise, social functioning and psychological distress.  The instrument has been validated in patients with cancer with a poor clinical status, who were demonstrated to report significantly lower levels of physical, social, role and emotional functioning and higher levels of fatigue, than those patients with a 
better clinical profile
38,39. Fur ther, the EORTC QLQ- C30 was sensitive to change over time from pre -chemotherapy to [ADDRESS_429450] that luminal estrogen receptor positive cell lines are sensi tive to CDK4/6 
19 
 
Protocol #: 13-559 
Version Date:   December 16, [ADDRESS_429451] hyperactivation of cyclin D1- CDK4/6. Comprehensive blockade of ER+ signaling pathway is synergistic 
with cell cycle arrest and results in clinical benefit and extends PFS in hormonal receptor positive metastatic breast cancer .  
 
Given the demons trated benefits of palbociclib in metastatic HR+ HER2 -negative breast cancer, there is interest in whether the benefits 
may translate into the adjuvant setting. Adjuvant endocrine therapy for breast cancer can be highly effective, however disease recurrenc e 
can occur, both in the first 5 years after a diagnosis and beyond 5 years. Trends in adjuvant endocrine therapy for HR+ breas t cancer are 
moving towards longer duration therapy.[ADDRESS_429452] cancer, palbociclib was generally well tolerated without significant adverse events, either as monotherapy or in combination with letrozole (see section 6.1.1 for specifics of toxicities observe d). This 
documented tolerability supports that notion t hat risk/benefit assessment will favor the addition of palbociclib in the adjuvant setting as 
well, where the risks of adding a novel therapy are weighted more heavily in a patient population whose life expectancy may not be limited by [CONTACT_972].  However , given the lack of safety data in the adjuvant curative setting, selection of a higher -risk subset of adjuvant breast 
cancer patients may appropriately balance potential risks and benefits of palbociclib therapy. Additionally, in clinical tria ls the 
comme rcially available AIs (letrozole, anastrozole, and exemestane) perform equivalently. In clinical practice, the toxicity profile of the 
three AIs is very similar and they are often used interchangeably, allowing design of a trial pairing palbociclib with an y of the three 
commonly used AIs. Tamoxifen is a commonly used agent in both pre -and post -menopausal patients, can be used as extended duration 
therapy, and early studies have suggested no interactions with palbociclib.  
 Based on these existing questions, this trial has been planned to determine the feasibility of longer duration combination th erapy with 
palbociclib and adjuvant endocrine  therapy in patients with higher- risk HR+ breast cancer.  
  
3. PARTICIPANT SELECTIO N 
 3.[ADDRESS_429453] be completed within 14 days prior to study entry.   
 
20 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
3.1.1 Patient/Disease Specifics:  
• Participants must have histologically confirmed hormone receptor positive (HR+) HER2 negative stage II  or stage III invasive 
breast cancer. Evaluation for metastatic disease is not required in the absence of symptoms.  
• Men and pre - and postmenopausal women  are eligible.   
 
3.1.2 Prior Treatment Specifics:  
• Participants may or may not have received (neo)adjuvant chemotherapy, but must be at least [ADDRESS_429454] dose of 
chemotherapy and/or biologic therapy, with no more than grade 1 residual toxicity at the time  of screening.  
• Participants may or may not have received adjuvant radiotherapy, but must be at least [ADDRESS_429455] dose radiotherapy, with no 
more than grade 1 residual toxicity at the time of screening.  
• If most recent therapy was surgery, participant s must be at least [ADDRESS_429456] demonstrated ability to tolerate adjuvant endocrine therapy, either tamoxifen or aromatase inhibitor (AI), by 
[CONTACT_345898] [ADDRESS_429457] 2 more years of adjuvant endocrine  therapy. 
  
3.1.4 ECOG performance status 0 -1 (see Appendix A).  
 
3.1.5 Age ≥18 years.  Because no dosing or adverse event data are currently available on the use of palbociclib in combination with 
endocrine  therapy in participants  <[ADDRESS_429458] normal organ and marrow function as defined below:  
• Absolute neutrophil count > 1,500/µL 
• Platelets > 100,000/µ L 
• Hemoglobin >  9g/dL  
• Total bilirubin < institutional upper limit of normal (patients with  documented Gilbert’s disease are allowed total bilirubin up to 
1.5X ULN)  
• AST (SGOT)/ALT (SGPT) <  2.5 X institutional upper limit of normal 
21 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
• Creatinine ≤  institutional upper limit of normal or creatinine clearance > 60 mL/min/1.73 m2 for subjects with creatinine levels 
above institutional normal . 
• Baseline QTc < [ADDRESS_429459] . Pregnancy testing does not need to be pursued in 
female patients  who are:  
o Age >  60 years; or  
o Age < [ADDRESS_429460] uterus and amenorrhea for 12 consecutive months or more  AND estrogen (estradiol) levels within  
postmenopausal  range ; or 
o Status-post bilateral oophorectomy, total hysterectomy, or bilateral tubal ligation.  
 
3.1.[ADDRESS_429461] that she is pregnant while participating in this study, she should inform her treating physician immediately.  Women of childbearing age (who do not meet the criteria defined in 3.1.7) , women who 
are made postmenopausal through use of GNRH agonists , and men are required to use adequate contraception for the duration of 
protocol treatment and for [ADDRESS_429462] dose of palbociclib. Adequate contraception is defined as one highly effective non-hormonal form of contraception or two effective forms of non- hormonal contraception by [CONTACT_5363]/or partner.  
 
Highly Effective Non -Hormonal Contraception  
Methods of birth control which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly are 
considered highly- effective forms of contraception.  
The following non- hormonal methods of contraception are acceptable:  
• True abstinence when this is in line with the preferred and usual lifestyle of the patient. [Periodic abstinence (e.g., cal endar, 
ovulation, symptothermal  post -ovulation methods) and withdrawal are not acceptable methods of contraception].  
• Male sterilization (with appropriate post -vasectomy documentation of the absence of sperm in the ejaculate). For female patients, 
the vasectomized male partner should be the sole partner.  
 
OR 
 
Effective Non -Hormonal Contraception  
Alternatively two of the following effective forms of contraception may be used instead:  
• Placement of non- hormonal intrauterine device (IUD) or intrauterine system (IUS). Consideration should be given to the type of 
device being used, as  there is higher failure rates quoted for certain types, e.g., steel or copper wire.  
22 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
• Condom with spermicidal foam/gel/film/cream/suppository.  
• Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.  
The use of barrier contraceptives should always be supplemented with the use of spermicide. The following should be noted:  
• Failure rates indicate that, when used alone, the diaphragm and condom are not highly effective forms of contraception. 
Therefore, the use of additional  spermicides does confer additional theoretical contraceptive protection.  
• However, spermicides alone are ineffective at preventing pregnancy when the whole ejaculate is spi[INVESTIGATOR_54073]. Therefore, spermici des 
are not a barrier method of  contraception a nd should not be used alone.  
 
It should be noted that two forms of effective contraception are required. A double barrier method is acceptable, which is de fined as 
condom and occlusive  cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/c ream /suppository 
 3.1.[ADDRESS_429463] be able to swallow and retain oral medication.  
 3.1.10 Ability to understand and the willingness to sign a written informed consent document.  
 
3.2 Exclusion Criteria  
 Participants who exhibit any of the following conditions at screening will not be eligible for admission into the study.  
 3.2.1 Concurrent therapy with other investigational agents.  
 
3.2.2 Prior therapy with any CDK4/[ADDRESS_429464] such as 
http://medicine.iupui.edu/clinpharm/ddis/table.aspx ; medical reference texts such 
as the Physicians’ Desk Reference may also provide this information.  As part of the enrollment/informed consent procedures, the patient will be  counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if 
the patient is considering a new over -the-counter medicine or herbal product.   
 
23 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
3.2.5 Current use of drugs that are known to prolong the QT i nterval (See Appendix F ) 
 
3.2.6 Subjects with organ allograft requiring immunosuppression.  
 
3.2.7 Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhy thmia,  uncontrolled diabetes mellitus,  or psychiatric illness/social situations that would 
limit compliance with study requirements.  Ability to comply with study requirements is to be assessed by [CONTACT_345899].  
 
3.2.[ADDRESS_429465] 5 years: ductal carcinoma in situ  of the breast, cervical cancer in situ , and basal cell or squamous cell carcinoma of the skin.  
 
Patients on combination antiretroviral therapy, i.e.  those who are  HIV- positive , are ineligible because of the potential for pharmacokinetic 
interactions or significant immunosuppression with Palbociclib.  
 
3.3 Inclusion of Women and Minorities  
 
Men and women are eligible for this protocol. Every effort wi ll be made to include patients from minority populations.  
 
4. REGISTRATION PROCEDU RES  
 
4.1 General Guidelines for DF/HCC and DF/PCC Institutions  
 
Institutions will register eligible participants with the DF/HCC Quality Assurance Office for Clinical Trials (QACT) central registration system. Registrations must occur prior to the initiation of therapy. Any participant not registered to the protocol before tr eatment begins 
will be considered ineligible and registration will be denied.  
 An investigator will confirm eligibility criteria and a member of the study team will complete the QACT  protocol -specific eligibility 
24 
 
Protocol #: 13-559 
Version Date:   December 16, [ADDRESS_429466]  begin protocol treatment  within 7 days. Issues that would cause treatment delays should be 
discussed with the Overall Principal Investigator (PI). If a participant does not receive protocol therapy following registration, the participant’s registration on the study may be canceled . Notify the QACT Registr ar of registration cancellations  as soon as possi ble.  
 
4.2 Recruitment Procedures
 
To enhance accrual and awareness of the trial, the study team will review clinic schedules and patient lists of medical oncologists at 
DF/HCC to identify eligible patients with hormone receptor positive  breast cancer.  
 Providers will be contact[CONTACT_345900], and subsequently approach the patient about participating in the trial.   
4.3 Registration Process for DF/HCC a nd DF/PCC Institutions  
 
The QACT registration staff is accessible on Monday through Friday, from 8:00 AM to 5:[ADDRESS_429467] registration line at  and 
follow the instructions for registering participants after hours.  
 The registration procedures are as follows:  
 
• Obtain written informed consent from the participant prior to the performance of any protocol specific procedures or assessments.  
 
• Complete the QACT protocol -specific eligibility checklist using the eligibility assessment documented in the participant ’s medical  
record and/or  research chart. To be eligible for registration to the protocol, the participant must meet all  inclusion and 
exclusion criterion  as described in the protocol and reflected on the eligibility checklist.  
 
Reminder : Confirm eligibility for ancillary studies at the same time as eligibility for the treatment protocol. Registration to both 
treatment and ancillary protocols will not be completed if eligibility requirements are not met for all studies.  
 
• Fax the eligibility checklist(s) and all pages of the consent form(s) to the QACT at   
• The QACT Registrar will (a) review the  eligibility  checklist , (b) register the participant on the protocol, and (c) randomize the 
participant when  applicable. 
25 
 

Protocol #: 13-559 
Version Date:   December 16, 2016  
 
• An email  confirmation of the registration and/or randomization will be sent to the Overall PI, study coordinator(s) from the Lead 
Site, treating invest igator and registering person immediately following the registration and/or randomization.  
 
4.[ADDRESS_429468]  begin protocol treatment within 7 days. I ssues that would cause treatment delays should be 
discussed  with the Overall PI.  If a participant does not receive protocol therapy following registration, the participant’s registration on the 
study may be canceled.  The Study Coordinator should be notified of cancellations as soon as possible.  
4.5 Registration Process for Other Investigative Sites  
 
To register a participant,  the following documents should be completed by [CONTACT_345901] 
 
•
 Clinic visit note documenting history and physical exam  
• Copy of required laboratory tests including: Hematology ( CBC with diff erential) , serum chemistries (creatinine and/or 
creatinine clearance, bilirubin, ALT, and AST)  
• Pathology report and documentation of ER/PR status and HER2 status.  
• ECG report  
• Signed participant consent form 
• HIPAA authorization form (if separate from the informed consent document) 
• Completed QACT Eligibility checklist  
  To complete the registration process, the Project Manager  will 
• register the participant on the protocol with the QACT  
• e-mail the confirmation of registration with the participan t study number, to the participating site 
• call the research nurse or data manager at the participating site and verbally confirm registration  
 
NOTE : Registration and randomization with the QACT can only be conducted during the business hours of 8:00 AM and 5:[ADDRESS_429469] Time Monday through Friday.  Same day treatment registrations will only be accepted with prior notice and 
26 
 

Protocol #: 13-559 
Version Date:   December 16, 2016  
discussion with the DF/HCC Project Manager .  
 
5. TREATMENT PLAN  
 
Treatment will be administered on an outpatient basis. Expected toxicities and potential risks as well as dose modifications for palbociclib 
are described in Section 6 (Expected Toxicities and Dosing Delays/Dose Modification). No investigational or commercial agents or therapi[INVESTIGATOR_345863]’s malignancy.  
 
5.1 Overall Study Design and Plan 
 
This is a non -randomized, open label study of the feasibility of longer duration combination therapy with palbociclib and adjuvant 
endocrine  therapy in patients with higher -risk HR+ breast cancer. Each subject will be assigned a unique identification number during 
screening, which will be used on all case report forms (CRFs) and correspondence regarding the subject.  
  
Treatment Description  
Agent  Precautions  Dose  Route  Schedule  Cycle 
Length  
Palbociclib  Given with food  
 125 mg  PO Daily on 
days 1- 21, 
followed by [CONTACT_345902]   
 28 days  
(4 weeks)  
One of the 
following agents : 
(1) Letrozole  
(2) Anastrozole  
(3) Exemestane 
(4) Tamoxifen  None for 
letrozole, 
anastrozole, 
tamoxifen; for 
exemestane: suggested to take after a 
meal  - Letrozole 2.5 
mg, or  
- Anastrozole 1 
mg, or  
- Exemestane 
25 mg  
- Tamoxifen 20 
mg  PO Daily, 
continuous  
  
27 
 
Protocol #: 13-559 
Version Date:   December 16, [ADDRESS_429470] dose of study treatment to establish eligibility and basel ine values.  This 
will be considered the baseline clinical evaluation. Subsequent changes from screening physical exam (PE) findings that meet the 
definition of an AE will be recorded on the AE page of the eCRF s. 
Demographic information and baseline characteristics will be collected at the Screening Visit. Standard demographic parameters include age, sex, and race/ethnicity (recorded in accordance with prevailing regulations). Baseline characteristics will include ECOG  PS 
(Appendix A), disease status, medical histories, prior and concomitant medications, and PE findi ngs. Relevant hormone receptor status 
will be collected.  
Additional pre -treatment evaluations, also found in section 3.1.6, are CBC with differential, chemistries, and EKG.  Pregnancy testing for 
screening should be obtained in appropriate patients, as def ined in Eligibility. Required results for initiation of protocol therapy include:  
• Absolute neutrophil count > 1,500/ µL 
• Platelets  > 100,000/ µL 
• Hemoglobin >  9g/dL  
• Total  bilirubin < institutional upper limit of normal (patients with  documented Gilbert’s disease are allowed total bilirubin up to 
1.5X ULN)  
• AST  (SGOT)/ALT (SGPT) <  2.5 X institutional upper limit of normal 
• Creatinine  ≤ institutional upper limit of normal or creatinine clearance > 60   mL/min/1.73 m2 for subjects with crea tinine levels 
above institutional normal . 
• Baseline QTc < 480 ms  
• Negative pregnancy test in appropriate patients  
• HgA1C (no required threshold level for initiation of therapy)  
 
28 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
5.3 Agent Administration  
 
5.3.1 Palbociclib  
 
Palbociclib 125 mg should be taken orally, once per day, with food.  If a dose is vomited, a replacement dose should NOT be taken.  If 
a dose is missed, and it is less than 6 hours from usual time of dosing, then patients may take that dose. Otherwise that dose should  be 
skipped and NOT  retaken ; patients should resume regular dosing the following day .  Patients who inadvertently take [ADDRESS_429471] skip the next day’s dose.  Patients should be instructed to record daily administration of the study drugs  in a drug diary 
(Appendix D). Treatment is continuous daily for 21 days, and then 7 days off, to complete a 28 day cycle.  
 On days when patient is scheduled for a clinic visit, the patient may take the oral medications at home or in the clinic.  
 In addit ion, patients will bring pi[INVESTIGATOR_345864], and pi[INVESTIGATOR_345865]: 
 Patients will be required to return all bottles of palbociclib as well as the completed drug diary at each study visit for drug accountability.  
Drug accountabi lity for palbociclib will be performed at each study visit prior to dispensing drug supply for the next cycle (s).  The number 
of remaining capsules/tablets will be documented and recorded.  
 To be considered compliant, each study patient must have taken  at least 80% of the planned number of doses of primary therapy based on 
the number of days of actual dose administration.  A study team member should review the drug diary for the endocrine therapy but does not need to perform a pi[INVESTIGATOR_345866], 
anastrozole, exemestane, or tamoxifen . 
 5.3.2 
Endocrine Therapy AI: letrozole, anastrozole, exemestane  
 
Endocrine therapy (letrozole, anastrozole, exemestane, or tamoxifen) should be taken orally, once per day, as per standard dosing. 
Ordering of endocrine therapy  self-administration relative to palbociclib self -administration is as per patient preference. A drug diary is 
supplied in Appendix D, for patients’ use to record dosing.   In addition, patients will bring pi[INVESTIGATOR_345867] .  . 
 
5.4 Genera l Concomitant Medication and Supportive Care Guidelines  
 
29 
 
Protocol #: 13-559 
Version Date:   December 16, [ADDRESS_429472] be recorded on the Prior and 
Concomitant Therapy page of the eCRF. The generic name [CONTACT_18467] (or trade name [CONTACT_178962]) must be specified al ong 
with the duration of treatment and indication for use. If concomitant medication/therapy is administered for an adverse event (AE), 
investigators will record that AE on the AE page of the eCRF. 
Supportive care medications are allowed at any time on trial.  Specifically, the following agents are permitted:  
• Antiemetics  
• Antidiarrheal therapy  
• Antiallergic measures such as corticosteroids and antihistamines 
• Bisphosphonates: Subjects being treated with bisphosphonates when they enter the study may continue the medication as long as  
the dose is stable. Subjects may also initiate bisphosphonate therapy while on protocol therapy if it is thought to be medically necessary.  
• Agents to assist in management of endocrine therapy -induced side effects (NSAIDs, gabapentin, duloxetine, venlafaxine, 
citalopram, etc)  
Growth factors, including GCSF, are not allowed on trial. Concurrent metformin is allowable.  
Cautious administration of a medication listed in Appendix F is permitted if absolutely medically necessary and with close QT  
monitoring. These cases must be disc ussed with the overall PI [INVESTIGATOR_345868] a medication from this list.  
The use of concurrent investigational or other antitumor therapi[INVESTIGATOR_014], other than endocrine therapy, is not permitted.  It is permitted to switch 
among members of the AI class (letrozole, anastrozole, and exemestane) , or from AI to tamoxifen or vice versa, while on trial.  
Missed doses of either endocrine therapy or palbociclib are not made up.  
If a patient finds she is not able to continue to tolerate endocrine therapy and is c onsidering stoppi[INVESTIGATOR_345869], she 
must stop all protocol therapy and will be removed from trial for lack of tolerability of combination therapy. For a patient who comes off 
protocol therapy, it is strongly encouraged to resume endocr ine therapy once symptoms resolve, or change to alternative endocrine 
therapy.  
30 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
Strong CYP3A inhibitors/inducers are not allowed on study.  Palbociclib is metabolized to multiple metabolites in a qualitati vely similar 
manner in rat, dog and human liver micr osomes.  In vitro, Palbociclib is primarily metabolized by [CONTACT_097]3A4 enzymes.  Co- administration 
with drugs that are CYP3A inhibitors and inducers may change the plasma concentrations of palbociclib in humans.  The concurr ent use 
of CYP3A inhibitors, including amprenavir, atazanavir, boceprevir, clarithromycin, conivaptan, delavirdine, diltiazem, erythromycin, 
fosamprenavir, indinavir, itraconazole, ketoconazole, lopi[INVESTIGATOR_054], mibefradil, miconazole, nefazodone, nelfinavir, posaconazole , ritonavir, 
saquinavir, te laprevir, telithromycin, verapamil, voriconazole, and grapefruit, grapefruit juice or any product containing grapefruit, are not 
allowed in the study.  The concurrent use of CYP3A inducers, including carbamazepi[INVESTIGATOR_050], felbamate, nevirapi[INVESTIGATOR_050], phenytoin, primi done, 
rifabutin, rifampin, rifanpi[INVESTIGATOR_2513], rifapentin, and St. John’s wort, are not allowed in the study.  This medication list may also be found in 
Appendix B. 
Concomitant use of moderate CYP3A inducers and CYP3A substrates is allowable on study, however precaution should be exercised for 
use of any concomitant medication. 
Proton pump inhibitors (PPI)  may be taken while on study, however it is recommended that the PPI  [INVESTIGATOR_345870] 12 hours from the time of 
palbociclib administration.  If needed, alternative antacid t herapi[INVESTIGATOR_345871] H2- receptor antagonists  and locally acting 
antacids.  H2-receptor antagonists should be administered with a staggered dosing regimen (twice daily). The dosing of  palbociclib should 
occur at least [ADDRESS_429473] 2 hours before or after palbociclib administration.  
 
Chronic immunosuppressive therapi[INVESTIGATOR_345872], including systemic corticosteroids.  Steroids given for physiological 
replacement, as anti -emetics or inhaled as well as short course of oral/topi[INVESTIGATOR_345873].  
The use of herbal medicine is not recommended during prot ocol treatment.  
Surgery is allowed during protocol therapy, however it is suggested to avoid nadir of counts at time of surgery. Patients pur suing surgery 
must hold palbociclib therapy [ADDRESS_429474] cycle of therapy should 
not be interrupted at 2 years. If a new cycle of therapy was started >  [ADDRESS_429475] cycle of therapy  is completed  < 1 week prior to the completion of two years, a new cycle should not be 
31 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
initiated.  Missed doses are not made up.  Any one of the following criteria will be reason to stop therapy before 2 years: 
 
• Development of recurrent disease by [CONTACT_41771], with need to change systemic therapy,  
• Intercurrent illness that prevents further administration of combination treatment,  
• Unacceptable toxicity of either palbociclib or endocrine therapy,  
• Participant demonstrates an inability or unwillingness to comply with the medication regimen and/or documentation 
requirements, including adherence to oral therapy, as determined by [CONTACT_345903], 
• Patient is unable to take either oral medication for more than 4  weeks, for any reason, 
• Provider preference for patient to come off study,  
• Participant decides to withdraw from the study, or  
• General or specific changes in the participant's co ndition render the participant  unacceptable for further treatment in the 
opi[INVESTIGATOR_80021] . 
 
If a patient finds she is not able to continue on combination therapy and must stop protocol therapy, she is strongly encoura ged to resume 
endocrine therapy  once symptoms resolve, or change to alternative endocrine therapy.  
 
5.[ADDRESS_429476]. Participants removed from 
study for seri ous adverse events (SAEs) will be followed until resolution or, if resolution is unlikely, until the event or sequelae stabilize. 
 
5.[ADDRESS_429477] may stop study 
treatment at any time for safety or personal reasons.  
Subjects who withdraw after signing the informed consent form (ICF) but before receiving study treatment will be replaced.   Participants will be removed from study when any of the criteria listed in Section 5.[ADDRESS_429478] be documented in the study -specific case report form (CRF). Alternative care options will be 
discussed with and, if necessary, provided for the participant.  
 A subject who has ceased to return for visits will be followed up by [CONTACT_2319], phone, or other means as much as possible to gathe r information 
32 
 
Protocol #: 13-559 
Version Date:   December 16, [ADDRESS_429479] immediately notify the Principal 
Investigator [INVESTIGATOR_193494] L. Mayer MD MPH at  
 
6. DOSING DELAYS/DOSE MODIFICATIONS  
 
Dose delays and modifications will be made as indicated in the following table(s). The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for dose delays and dose modifications. A copy of the CTCAE version 4.0 can be downloaded from the CTEP website  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm .  See Appendix C for an overview of CTCAE. 
 All adverse events experienced by [CONTACT_234311], through the stu dy and 
until [ADDRESS_429480]. Participants continuing to experience toxicity at the off study visit may be contact[CONTACT_143027].  
 
6.1 Toxicity Management 
 
6.1.1 
Toxicity management – Palbociclib  
 Every effort should be made to administer study treatment on the planned dose and schedule. However, in the event of significant treatment-related toxicity, administration of palbociclib may need to be adjusted as described in section 6.3.  In the event treatment interruption is deemed necessary for either palbociclib or the endocrine therapy , treatment with the other medication will continue as 
planned.  
As per section 5.4, treatment with growth factors  is not allowed on trial.  
 
If the retreatment parameters (see section 6.3) are met within [ADDRESS_429481] not been met after 4 weeks of dose interruption (including the scheduled 1 week off treatment), the 
patient should permanently discontinue palbociclib treatment.   
33 
 

Protocol #: 13-559 
Version Date:   December 16, [ADDRESS_429482] 
palbociclib held for up to 5 weeks after surgery.  Patients should continue endocrine therapy if palbociclib is held for surgery.  
 
Patients discontinuing palbociclib treatment due to treatment -related toxicity will come off study, but should continue on endocrine therapy  
as per the investigator’s discretion.  
 6.1.2 
Toxicity management – Endocrine Therapy  
 No dose reduction for endocrine therapy is permitted, but dosing inter ruptions are allowed (see section 6. 2.).  Treatment interruptions for up 
to 3 cumulative weeks for endocrine therapy -related toxicities or personal reasons are allowed as per the investigator’s best medical 
judgment.  Rotation of AI therapy among the three approved agents is also allowed,  as is change to AI from tamoxifen or change to tamoxifen 
from AI.  
 Patients discontinuing endocrine therapy due to treatment -related toxicity will be discontinued from protocol therapy and come off study.  
Further endocrine therapy is encouraged and is at the discretion of the treating physician.  
 
6.2 Palbociclib Dose Modifications/Delays
 
 
In the event of significant treatment -related toxicity, palbociclib dosing may be interrupted or delayed and/or reduced as described be low.  
In the event of multiple toxicities, dose modification should be based on the worst toxicity observed.  Patients are to be instructed to notify Investigators at the first occurrence of any adverse sign or symptom.  
Cycles should be [ADDRESS_429483] ied, the patient 
may need to return to the clinic to receive new drug supply.  
34 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
If a new cycle of therapy was started >  [ADDRESS_429484] 2 years.  
6.2.1 Palbociclib Dosing Interruptions/Delays  
Patients experiencing the following ad verse events should have their treatment of palbociclib interrupted/delayed until criteria for 
retreatment are met:  
• Uncomplicated Grade 3 or 4 neutropenia (ANC<1000/mm3); 
• Grade 3 or 4 neutropenia (ANC<1000/mm3) associated with a documented infection or fev er ≥38.5°C , 100.4°F ; 
• Grade 2 or higher  thrombocytopenia (Platelet < 75,000/mm3); 
• Grade ≥ 3 non- hematologic toxicity (including, nausea, vomiting, diarrhea, and hypertension only if persisting despi[INVESTIGATOR_345874]); 
• Grade 2 non- hematologic toxicity persisting despi[INVESTIGATOR_345875] 4 weeks;  
• Grade 3 QTc prolongation (QTc ≥[ADDRESS_429485] two separate ECGs);  
• Grade [ADDRESS_429486];  
• In case of concurrent > 3x ULN ALT and 2x ULN Total Bilirubin, palbociclib will be permanently discontinued.  
Patients should not hold or discontinue palbociclib for side effects potentially or likely related to concomitant antihormona l therapy (e.g., 
grade 3 or long lasting grade 2 joint pain) as per the investigator’ s judgment. 
Appropriate follow up assessments should be performed until adequate recovery occurs as assessed by [CONTACT_345904].  
6.2.2 Palbociclib Retreatment C riteria  
Retreatment with palbociclib  following treatment interruption for treatment related toxicity or at the start of a new cycle  that  requires a 
clinic visit (Cycles 2, 3, 4, 6, 8, 10, 12, 15, 18, 21, 24) may not occur until all of the following parameters have been met:  
• Platelet count ≥  75,000/mm3; 
• ANC ≥  1000/mm3 and no fever;  
35 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
• Any persistent grade 2, grade [ADDRESS_429487] recovered 
to Grade ≤ 1 or baseline.  
• Only if treatment was held for QTc prolongation: QTc < 480 msec and potential reversible causes (eg, electrolyte imbalance, 
concomitant medications known to prolong QTc) corrected.  If QTc remains above 480 msec, cardiology should be consulted and 
the ECG be monitored more frequently as per the investigator’s best  medical judgment until QTc ≤480 msec. 
 
The start of new cycles that require labs without a clinic visit may begin without receiving results for required labs  (CBCs) . The nurse or 
physician should contact [CONTACT_345905] a treatment hold are noted.  Lab results must be available by [CONTACT_2006] [ADDRESS_429488] not been met after 4 weeks of dose interruption (including the scheduled 1 week off treatment), the patient s hould 
permanently discontinue palbociclib treatment.  
 
6.2.[ADDRESS_429489] ing Grade 2 (< 4 weeks) treatment -related toxicity.  However, 
investigators should always manage their patients according to their medical judgment based on the particular clinical circum stances.  
In case of a Grade 2 toxicity lasting for > 4 weeks or a Grade 3 toxicity (both assessed in the presence of maximum supportive care as 
judged by [CONTACT_093]), dose reduction is recommended for the subsequent cycles. Taking palbociclib according to recommendation 
(i.e., with food) should be reinforced and confirm ed.  Dose reduction of palbociclib by [CONTACT_132435] , and, if needed, by [CONTACT_68000] 
(Table 1) may be  recommended depending on type and severity of the toxicity encountered. Once a dose has been reduced for a given 
patient, all subsequent cycles should  be administered at that dose level, unless further dose reduction is required.  Dose re -escalation is not 
allowed. Patients requiring more than 2 dose reductions will be discontinued from the study.  
Table  1. Dose Levels  
36 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
Dose Level  Palbociclib for 3 out of 4 weeks (3/1 schedule)  
Starting dose  125 mg/d  
-1 100 mg/d  
-2 75 mg/d  
 Discontinue Study Treatment  
 
Palbociclib recommended dose modifications for treatment -related toxicities requiring treatment interruption/delay or persisting despi[INVESTIGATOR_345876]  2.  
  
37 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
Table  2. Palbociclib Dose Modifications for Treatment Related Toxicities Req uiring Treatment Interruption/Delay or Persisting 
Despi[INVESTIGATOR_345877].  
 
Toxicity  Intervention with Palbociclib 
Uncomplicated Grade  3 neutropenia  
(ANC ≥500 - <1000 /mm3) 
 
 
 • 1st occurrence: Hold drug. If ANC recovers (ANC > 1000) within 2 weeks, resume at same dose.  
• If ANC takes longer than 2 weeks to recover (ANC >1000), but within 4  weeks, then resume drug and 
decrease drug by 1 dose level.  
• Recurrent uncomplicated Grade 3: Hold drug.  If ANC recovers (ANC >  1000) within 2 weeks, resume 
drug and decrease drug by 1 dose level.  
Grade  3 neutropenia  (ANC<1000/mm3) 
associated with a documented 
infection 
or fever ≥38.5° 
 • Hold drug. If ANC recovers (ANC > 1000) within 2 weeks, resume drug and decrease drug by 1 dose level.  
• If ANC takes longer than 2 weeks to recover (ANC >1000), but within 4  weeks, then resume drug and 
decrease drug by 2 dose levels.  
• If these parameters have not been met after 4  weeks of dose interruption (including the scheduled 1 week 
off treatment), the patient should permanently discontinue Palbociclib.  
Grade 4 neutropenia (ANC < 
500/mm3)  
 • First occurrence: Hold drug. Resume once ANC > 1000 and decrease dose by 1 dose level.  
• Recurrent Grade 4 neutropenia:  Hold drug. Resume once ANC > 1000 and decrease dose by [CONTACT_345906].  
Grade 3 or 4 thrombocytopenia  
(platelet count < 50,000)  • 1st occurrence: Hold drug until plt > 75,000, then resume drug and decrease by 1  dose level.  
• Recurrent Grade 3 thrombocytopenia: hold drug until plt > 75,000, then decrease drug by [CONTACT_345907].  
Grade  ≥3 non -hematologic toxicity  
(including, nausea, vomiting, diarrhea,  
and hypertension only if persisting 
despi[INVESTIGATOR_4573] ); • 1st occurrence:  Hold drug until toxicity decreases to < Grade 1 or to baseline, then resume drug and 
decrease by 1dose level.  
• If toxicity  takes longer than 2 weeks to recover to < Grade 1 , but within 4 weeks, then resume drug and 
decrease drug  by 2 dose level s. 
• Recurrent toxicity: Hold drug until toxicity decreases to <  Grade 1 or to baseline, then decrease drug by [CONTACT_345908].  
Grade 2 non -hematologic toxicity 
persisting despi[INVESTIGATOR_4571] ,  deemed unacceptable in the 
investigator’s judgment , and lasting at 
least 2 weeks ; • 1st occurrence:  Hold drug until toxicity decreases to < Grade 1 or to baseline, then resume drug at same 
dose level . 
• Recurrent toxicity: Hold drug until toxicity decreases to < Grade 1 or to baseline, then resume drug and 
decrease by 1 dose level . 
38 
 
Protocol #: 13-559 
Version Date:   December 16, [ADDRESS_429490]  • 1st occurrence: Hold drug until clinically stable and decreases to ≤ Grade 1, then resume drug and decrease 
by 1 dose level  
• 2nd occurrence: Discontinue drug  
LFTs  
Concurrent > 3XULN SGPT/ALT and 
2X ULN total bilirubin  (Hy’s Law)  
 Discontinue Palbociclib permanently.  
39 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
QTc prolongation management  
In the event of QTc  prolongation, possible alternative reversible causes such as serum electrolytes abnormalities, or usage of concomitant 
medications with the potential to prolong the QTc interval should be evaluated. If such reversible causes are identified, the n they shou ld be 
corrected accordingly (i.e., correction of electrolyte abnormalities with supplements to within normal limits and/or discontinuation (if 
possible) of concomitant medications known to prolong the QT interval [see Appendix F ]).  
 
All cases of QTc prolongation should be discussed with the overall PI [INVESTIGATOR_345878]. 
Recommended dose modifications in the event of QTc prolongation are provided in the Table below .  
Palbociclib Dose Modifications in the Event of  QTc Prolongation  
 
 Toxicity (NCI CTC Grade, Version 4.0)  
 Grade 2 QTc prolongation  
 (>480 and <500 msec, or 60 msec above baseline)  Grade 3 QTc prolongation  
(≥ 501 msec) Grade 4 QTc 
prolongation (≥ 501 
msec or >60 ms change 
from baseline and life -
threatening signs 
including Torsades de 
points)  
Reversible cause 
identified  Treat reversible cause  
Initiate more frequent ECG monitoring according 
to investigator’s best medical judgment until QTc ≤480 msec  
Continue at the
 same dose level  (1) Treat reversible cause  
Withhold treatment until QTc <500 msec  
Resume treatment at the same dose level . 
Monitor ECG more frequently as per investigator’s best 
medical judgment until QTc ≤480 msec.   Permanently 
discontinue  
No reversible cause 
identified  Consult cardiology and initiate more frequent ECG monitoring according to investigator’s best medical judgment until QTc ≤480 msec;  
Continue at the 
same dose level  (1) Withhold treatment until QTc <500 msec  
Resume treatment at  the next lower dose  level (2) 
Consult cardiology and monitor ECG more frequently as per 
investigator’s best medical judgment until QTc ≤480 msec.  Permanently 
discontinue  
1. If the QTc remains above 480 msec more than 2 cycles or if Grade 2 QTc prolongation recurs in the absence of other alternative causes or despi[INVESTIGATOR_345879], dose adjustment and/or discontinuation should be considered in consultation with a cardiologist and the s tudy medical monitor, taking into 
account the emerging safety data from palbociclib  trials and the investigator’s best medical judgment.  
2. If the Grade 3 QTc prolongation occurs again after one dose reduction, further dose adjustment and/or discontinuation should be discussed with study medical moni tor in consultation with a cardiologist, taking intoconsideration the emerging safety data from palbociclib trials and the  investigator’s best medical judgment.  
40 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
If the QTc remains at  >480 msec for more than 2 cycles or if Grade 2 QTc prolongation recurs i n the absence of other alternative causes or 
despi[INVESTIGATOR_4574], dose adjustment and/or discontinuation should be considered in consultation with a cardiologist 
and the study monitor.  
6.2.4 Dose modifications/delays – Endocrine Therapy  
 
No dose reduction for endocrine therapy is permitted, but dosing interruptions are allowed.  Treatment interruptions for up to 3 cumulative 
weeks for endocrine therapy -related toxicities or personal reasons will be performed as per the investigator’s best med ical judgment.  
Palbociclib should not be held during endocrine therapy interruption, unless palbociclib is on hold for a separate re ason as described in 
section 6.2.1.  Rotation of AI therapy among the three approved agents is also allowed, as is change to AI from tamoxifen or change to tamoxifen from AI .  
 If a patient requires [ADDRESS_429491] to be removed from study for intolerance of combination therapy. Once recovered, the 
patient should be encouraged to continue adjuvant endocrine therapy.  
 
7. ADVERSE EVENTS:  LIS T AND REPORTING REQUIREMENTS  
 
Adverse event (AE) monitoring and reporting is a routine part of every clinical trial.  The following list of reported and/or potential AEs 
(Section 7.1) and the characteristics of an observed AE (Section 7.2) will determine whether the event requires expedited reporting in addition  to routine  reporting.  
 
7.[ADDRESS_429492](s) for Palbociclib  
 
41 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
The primary anticipated toxicity of palbociclib is neutropenia.  In the phase I, dose -escalation trial of palbociclib  alone in advanced 
cancers35, neutropenia was the only dose -limiting toxicity (DLT).  Grade  3 neutropenia during cycle 1 was observed in 3/22 patients 
receiving palbociclib 125 mg PO daily, with no grade 4 neutropenic events observed.  Based on this result, 125 mg PO daily be came the 
recommended phase 2 dose (RP2D).  Other hematologic AEs of gra de [ADDRESS_429493] common non- hematologic AEs of grade 3 or greater during cycle 1 were fatigue, nausea, 
and abdominal pain (each occurring in 2 of 41 pati ents).  Of note, there were no complicated hematologic AEs documented, and all 
hematologic AEs resolved during the off -drug period of a 3 week on/[ADDRESS_429494] cancer, the only toxicities > grade 3 observed were transient neutropenia (50%) 
and thrombocytopenia (21%).[ADDRESS_429495] treatment delay for 
neutropenia was 58 days, and the median duration of treatment delay until recovery was 5 days (range 1- 16 days). ([COMPANY_007] internal data). In 
general, hematologic abnormalities were adequately managed with standard supportive care, were not complicated, and resolved during the 
drug hold with no cumulative toxicity noted.  
 In the phase I, dose -escalation trial of palbociclib alone in advanced cancers,
35 QT interval changes were also evaluated in detail.  While 26 
of 41 patients had a maximum increase of <[ADDRESS_429496](s) for Commercial Agent(s) – AIs ( letrozole, anastrozole , exemestane)  and Tamoxifen  
 
The most common adverse events experienced with use of AIs include hot flashes, arthralgias , and gradual loss o f bone density.  The most 
common adverse events experienced with use of tamoxifen include hot flashes, night sweats, and vaginal discharge. Venous thromboembolic 
disease and endometrial cancer are rare risks of tamoxifen.  
 Package inserts for the 3 AIs and tamoxifen can be found at:  
• Letrozole: 
http://www.pharma.us.novartis.com/cs/www.pharma.us.novartis.com/product/pi/pdf/Femara.pdf  
• Anastrozole: http://editor.apppharma.com/PIs/Anastrozole_451221_Apr_10.pdf  
• Exemestane: http://patient.cancerconsultants.com/druginserts/Exemestane.pdf  
• Tamoxifen: http://patient.cancerconsultants.com/druginserts/Tamoxifen.pdf  
 
 
7.2 Adverse Event Characteristics  
 
42 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
• CTCAE term (AE description) and grade:  The des criptions and grading scales found in the revised NCI Common Terminology 
Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for AE reporting.  All appropriate treatment areas should ha ve 
access to a copy of the CTCAE version 4.0.  A copy of t he CTCAE version 4.0 can be downloaded from the CTEP web site 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm . 
 
• For expedited reporting purposes only:   
- AEs for the agent (s) that are listed above  should be reported only if the adverse event varies in nature, intensity or frequency 
from  the expected  toxicity  information which is provided.  
- Other AEs for the protocol  that do not require expedited reporti ng are outlined in the next section (Expedited Adverse Event  
Reporting ) under the sub -heading of Protocol -Specific Expedited Adverse Event Reporting Exclusions.  
 
• Attribution  of the AE:  
- Definite – The AE is clearly related  to the study treatment.  
- Probable – The AE is likely related to the study treatment.  
- Possible – The AE may be related  to the study treatment.  
- Unlikely – The AE is doubtfully related to the study treatment. 
- Unrelated – The AE is clearly NOT related  to the s tudy treatment.  
 
7.[ADDRESS_429497]  report to the Overall PI [INVESTIGATOR_102802] (SAE ) that occur s after the initial dose of study treatment, during 
treatment, or within [ADDRESS_429498] dose of treatment on the local institutional SAE form. Serious AEs will be followed until resolution or, if resolution is unlikely, until the event or sequelae stabilize.  
 For multi- institution studies where a DF/HCC investigator is serving as the Overall Principal Investigator, each participating institution  
must  abide by [CONTACT_102841]/HCC. This applies to any medical event equivalent to a n unexpected grade 2 or 3 
with a possible, pr obable or definite attribution, unexpected grade 4 toxicities, and grade 5 (death) regardless of study phase or attribution.  
 7.3.1 
DF/HCC Expedited Reporting Guidelines  
 
Investigative sites within DF/HCC and  DF/PCC will report SAEs directly to the DFCI Office for Human Research Studies (OHRS) 
per the DFCI IRB  reporting policy.  
 
43 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
Other investigative sites will report SAEs to their respective IRB according to the local IRB’s policies and procedures in reporting  
adverse events. A copy of the submi tted institutional SAE form should be forwarded to the Overall PI [INVESTIGATOR_198016].   
 
Table 3: DF/HCC Reportable AEs  
 
 
 
Attribution  DF/HCC Reportable AEs  
Gr. 2 & 3 AE  
Expected  Gr. 2 & 3 AE 
Unexpected  Gr. 4 AE Expected  Gr. 4 AE  
Unexpected  Gr. 5 AE 
Expected or 
Unexpected  
Unrelated  
Unlikely  Not required  Not required  5 calendar days# 5 calendar days  24 hours*  
Possible  
Probable  
Definite   
Not required   
5 calendar days   
5 calendar days#  
5 calendar days   
24 hours*  
# If listed in protocol as expected and not requiring expedited reporting, event does not need to be reported.  
 
* For participants enrolled and actively participating in the study or for AEs occurring within [ADDRESS_429499] 
intervention, the AE should be reported within 24 business hours  of learning of the event.  
 
 
The Overall PI [INVESTIGATOR_345880].  
 
7.4 Expedited Reporting to the Food and Drug Administration (FDA)  
 
The Overall PI , as study sponsor, will be responsible for all communications with the FDA. The Overall PI  [INVESTIGATOR_57895], 
regardless of the si te of occurrence, any serious adver se event that meets the FDA’s criteria for expedited reporting following the reporting 
requirements and timelines set by [CONTACT_1622].  
 
7.[ADDRESS_429500] awareness of the event (immediately if the event is fatal or life- threatening), the Overall PI [INVESTIGATOR_345881] (“SAE,” as defined below) for which reporting is required  under this provision (as 
described below).  Such SAEs are to be reported for s tudy subjects or individuals otherwise exposed to the [COMPANY_007] Product as described 
below.  The Overall PI [INVESTIGATOR_345882], even if complete information is not yet 
available.  
44 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
 
Principal Investigators will report SAEs using Form FDA 3500A (MedWatch).  The Reportable Event Fax Cover Sheet  provided by [CONTACT_345909].      7.5.[ADDRESS_429501] to causality, that is life -threatening (ie, causes an immediate risk of death) or that results in 
any of the following outcomes: death; in- patient hospi[INVESTIGATOR_1081]; persistent or significant 
disability or incapacity (ie, substantial disruption of the ability to conduct normal life functions); or a congenital anomal y or birth defect.  
Any other medical event that, in the medical judgment of the Principal Investigator, may jeopardize the subject or may require medical or surgical intervention to prevent one of the outcomes listed above is also considered an SAE.  A planned medical or surgical procedure is not, in itself, an SAE.   
 7.5.2 
Exposure During Pregnancy, Exposure During L actation, Occupational Exposure  
 Even though there may not be an associated SAE, exposure to the Palbociclib during pregnancy, exposure to the Palbociclib dur ing 
lactation, and occupational exposure to the Palbociclib are reportable to [COMPANY_007].   
 7.5.3 
Hy’s Law  Cases  
 Cases of potential drug -induced liver injury as assessed by [CONTACT_201383] (“Hy’s Law Cases”) are also reportable to [COMPANY_007].   If a 
participan t develops abnormal values in aspartate transaminase (AST) or alanine transaminase or both, concurr ent with abnormal 
elevations in total bilirubin and no other known cause of liver injury, that event would be classified as a Hy’s Law Case.   7.5.[ADDRESS_429502] dose of the Palbociclib through 30 calendar  
45 
 
Protocol #: 13-559 
Version Date:   December 16, [ADDRESS_429503]’s last study 
visit, whichever comes first. All Adverse Events must  be reported in routine study data submissions  to the Overall PI [INVESTIGATOR_102805] f orms .  AEs reported through expedited processes (e.g.,  reported to the IRB, FDA, etc.)  must also be reported in routine 
study data submissions.  
  
8. PHARMACEUTICAL INFORMATION  
 
A list of the adverse events and potential risks associated with the investigational or other  agents administered in this study can be found in 
Section 7.1.  
 
8.1 Palbociclib  
 
8.1.1 
Description  
 
46 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
 
 
Chemical name:  6-acetyl -8-cyclopentyl -5-methyl -2-(5-(pi[INVESTIGATOR_9482] -1-yl)pyridin -2-ylamino)pyrido[2,3- d]pyri midin -7(8H) -one. 
Chemical formula: C24H29N7O2  
Molecular weight: 447.54 . 
Half life: ~27 hours.  
Plasma protein binding of palbociclib: ~85%  
Plasma protein binding of PF- 05089326 (the lactam of palbociclib, one of the main metabolites present in plasma) : 95%  
 
Palbociclib ( IC50 = 11 nM; Ki = 2 nM ) is metabolized to multiple metabolites in a qualitatively similar manner in rat, dog and 
human liver microsomes.  In vitro, Palbociclib  is primarily metabolized by [CONTACT_097]3A4 enzymes.  Information on potential drug 
interactions can be found in section 5.4.   
 
8.1.2 Form  
 
Palbociclib will be supplied by [CONTACT_345910] 75 mg, 100 mg, or 125 mg equivalents of palbociclib free base.  [COMPANY_007] will 
supply the oral drug formulation to sites in High Density Polyethylene (HDPE) bottles containing 75 mg, 100 mg, or 125 mg capsules.  
The capsules can be differentiated by [CONTACT_4668] (see below).  N
N N O HN
N
N
N
HCH3O CH3
47 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
Table 4. Palbociclib capsule characteristics  
Dosage  Capsule color  Capsule size  
75 mg  Sunset Yellow/Sunset Yellow  2 
100 mg  Caramel/Sunset Yellow  1 
125 mg  Caramel/Caramel  0 
 
8.1.3 Storage and Stability  
 
Storage conditions stated in the Single Reference Safety Document (i.e., Investigator’s Brochure (IB), [LOCATION_002] Package Insert 
(USPI), Summary of Product Characteristics (SPC), or Local Product Document (LPD)) will be superseded by [CONTACT_4671].  
Palbociclib capsules should be stored at controlled room temperature (15 -30°C, 59- 86°F) in their original container.  
Investigators and site staff are reminded to check temperatures daily (i.e. manually or by [CONTACT_345911]) 
and ensure that thermometers are working correctly as required for proper storage of investigational products.  These include  thermometers 
for room storage.  Any temperature excursions must be reported to Pfi zer.  The investigational products must be stored as indicated.   
Deviations from the storage requirements, including any actions taken, must be documented and reported to [COMPANY_007].   
Once a deviation is identified, the investigational products (palbociclib) must be quarantined and not used until [COMPANY_007] provides 
documentation of permission to use the investigational product.  
Medication should be kept in a secured locked area at the study site in accordance with applicable regulatory requirements.  Returned 
medication should be stored separately from medication that needs to be dispensed.  
 
8.1.[ADDRESS_429504] for co -administration of palbociclib and any of the three AIs.  
 
8.1.5 
Handling  
 
Qualified personnel, familiar with procedures that minimize undue exposure to themselves and the environment, should undertak e the 
preparation, handling, and safe disposal of the chemotherapeutic agent in a self -contained and protective environment.  
 
48 
 
Protocol #: 13-559 
Version Date:   December 16, [ADDRESS_429505] until their next study visit.  Unused drug and/or empty bottles should be returned to the site at the next study visit.  Unused returned 
medication MUST NOT be re-dispensed to patients.  
Palbociclib is an agent that must be handled and administered w ith care.  Patients should be instructed to keep their medication in the 
bottles provided and not transfer it to any other container.  Due to possible unknown hazards associated with topi[INVESTIGATOR_196319], capsules must not be opened and/or emptied into any vehicle for oral ingestion; capsules must be 
swallowed intact.  
Only a single capsule strength will be dispensed to the patient at each dispensing visit.  In the event of dose modification, request should be 
made of the patient to return all previously dispensed medication to the clinic and new capsules will be dispensed. 
 
8.1.[ADDRESS_429506] managers at:   
 
8.1.[ADDRESS_429507] of the inventory and disposition of the agent (investigational or free of charge) using the NCI Drug Accountability Record or another comparable drug accountabil ity form. 
49 
 

Protocol #: 13-559 
Version Date:   December 16, 2016  
(See the CTEP website at http://ctep.cancer.gov/protocolDevelopment   for the “Policy and Guidelines for Accountability and Storage of 
Investigational Agents” or to obtain a copy of the drug accountability form.)  
 
8.1.[ADDRESS_429508] be adequately documented.  
 
8.2 Letrozole  
 
8.2.1 Description  
Letrozole  tablets for oral administration contains 2.5 mg of letrozole, a nonsteroidal aromatase inhibitor  (inhibitor of estrogen synthesis). It 
is chem ically described as 4,4' -(1H-1,2,4- Triazol- 1- 
ylmethylene)dibenzonitrile, and its structural formula is  Letrozole is a white to yellowish crystalline powder, practically odorless, freely 
soluble in dichloromethane, slightly soluble in ethanol, and practica lly insoluble in water. It has a molecular weight  of 285.31, empi[INVESTIGATOR_9506] C 17H11N5, and a melting range of 184°C -185°C.  
 8.2.2 
Form  
Letrozole is available in 2.5 mg tablets . 
 8.2.3 
Storage and Stability  
Store at 25°C (77°F); excursions permitted to 15- 30°C (59- 86°F) [see USP Controlled Room  
Temperature].  
 8.2.[ADDRESS_429509] to meals.  
50 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
 
8.3 Anastrozole  
 
8.3.1 Description  
Anastrozole tablets for oral administration contain 1 mg of anastrozole, a non- steroidal aromatase inhibitor. It is chemically described as 
1,3-Benzenediacetonitrile, a, a, aˈ,aˈ -tetramethyl -5-(1H-1,2,4- triazol -1-ylmethyl). Anastrozole is an off -white powder with a molecular 
weight of 293.4. Ansastrozole has moderate aqueous solubility (0.5 mg/mL at 25˚C); solubility is independent of pH in the physiological range.  Anastrozole is freely soluble in methanol, acetone, ethanol, and tetrahydrofuran, and very soluble in acetonitrile.  
 8.3.2 
Form  
Anastrozole is available in 1 mg tablets.  
 8.3.3 
Storage and Stability  
Store at 20˚ to 25˚C (68˚ - 77˚F) [see USP Controlled Room Temperature].  
 8.3.[ADDRESS_429510] for co -administration of palbociclib and anastrozole.  
 8.3.5 
Availability  
Anastrozole is commercially available.   8.3.6 
Administration  
The recommende d dose of anastrozole is one 1mg tablet taken once daily.  
 
8.4 Exemestane  
 
8.4.1 Description  
Exemestane tablets for oral administration contain 25 mg of exemestane, an irreversible, steroidal aromatase inactivator. Exemestane is 
chemically described as 6 -methylenandrosta -1,4-diene -3,17- dione. The active ingredient is a white to slightly yellow crystalline powder 
with a molecular weight of 296.41. Exemestane is freely soluble in N, N -dimethylformamide, soluble in methanol, and practically 
insoluble in water.  
 
51 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
8.4.2 Form  
Exemestane is available in 25 mg  tablets.  
 
8.4.3 Storage and Stability  
Store at 25°C (77°F); excursions permitted to 15°- 30°C (59°- 86°F) [see USP Controlled Room Temperature]. 
 8.4.[ADDRESS_429511] for co -administration of palbociclib and exemestane. 
 8.4.5 
Availability  
Exemestane is commercially available.   8.4.6 
Administration  
The recommended dose of exemestane is 25 mg once daily after a meal.  
 
8.5 Tamoxifen  
 
8.5.1 Description  
Tamoxifen tablets for oral administration contain 30.4 mg of tamoxifen citrate which is equivalent to 20 mg of tamoxifen, a nonsteroidal antiestrogen. Tamoxifen is the trans- isomer of a triphenylethylene derivative. The chemical name [CONTACT_832] (Z)2 -[4-(1,2-diphenyl -1-butenyl) 
phenoxy] -N, N- dimethylethanamine 2- hydroxy- 1,2,3-  propan etricarboxylate (1:1). Tamoxifen citrate has a molecular weight of 563.62, the 
pKa' is 8.85, the equilibrium solubility in water at 37°C is 0.5 mg/mL and in 0.02 N HCl at 37°C, it is 0.2 mg/mL.  
 8.5.[ADDRESS_429512] ability  
Store at controlled room temperature, 20- 25°C (68- 77°F)  [see USP Controlled Room Temperature]. 
 
8.5.[ADDRESS_429513] for co -administration of palbociclib and tamoxifen . 
 
52 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
8.5.5 Availability  
Tamoxifen is commercially available.  
 8.5.6 
Adm inistration  
The recommended dose of tamoxifen is 20 mg once daily.  
9. BIOMARKER, CORRELATI VE, AND SPECIAL STUDIES  
 9.1 Research Specimen Collection  
 
A whole blood sample  will be collected pre treatment  on Cycle 1 Day 1 to be retained for potential pharmacogenomic  analyses related to 
drug response or adverse drug reactions. If sample is not collected on C1D1 it can be collected any time prior to the end of protocol treatment.   Methods: 1 10ml  EDTA tube will be collected pre treatment on the Cycle 1 Day 1 visit for all participating patients. Specimens should be 
labeled with the assigned sample ID  number, date of collection, time point of collection, and protocol number.   
 
• Complete the 13-559 Specimen Requ isition form found in Appendix E. 
• Ship the same day as collec tion at ambient temperature by [CONTACT_345912]:  
Dana Farber Cancer Institute  
 
 
 
All research blood  samples should arrive during the week by [CONTACT_345913] .   
 Email  and DFCI Study Coordinator with the sample information and tracking information the day before 
shippi[INVESTIGATOR_36406]. 
 
  
 
53 
 

Protocol #: 13-559 
Version Date:   December 16, [ADDRESS_429514] be drawn on a Friday or the day before a holiday, sites can aliquot the whole blood into 4 cryovials and freeze them at -
80C, then ship on dry ice M onday- Thursday.  
 The coordinating center study coordinator will track the research blood specimens using CaTissue.  Upon receipt of an email notification regarding sample sh ipment from a participating site, the coordinating center study coordinator will log in the sample information into 
CaTissue.  When the sample is received by [CONTACT_345914]/HCC Core Blood and Tissue Bank lab, the confirmation of receipt and 
specimen location information will be added to CaTissue.  CaTissue will contain a complete record of the research blood sampl es that are 
collected as part of this study.  All samples will be de -identified and assigned a linked sample ID number on arrival; all participant identification will be removed.    
In patients who develop recurrent disease during protocol therapy, tumor biopsy and collection of a sample of whole blood are  strongly 
recommended. Samples may be analyzed by [CONTACT_345915]. recurrent tumor  to evaluate pathways of palbociclib 
and endocrine resistance.  Biopsy and collection of blood at progression are not part of this clinical trial.  
 
9.2 Quality of Life  
The QOL survey  (EORTC QLQ- C30) will be administered at Baseline/Cycle 1 day 1, Cycle 3 day 1, C ycle 6 Day 1, Cycle 12 D ay 1, 
Cycle 18 Day 1 , and End- of-Treatment visit . The survey will be administered as  paper copi[INVESTIGATOR_345883], and all sites should retain copi[INVESTIGATOR_345884]. Patients can complete the survey either before or after the provider visit. Copi[INVESTIGATOR_345885] I . 
 9.3 Drug Adherence
 
Drug diaries ( Appendix D ) will be maintained for patients to capture adherence to oral palbociclib and endocrine therapy . Diaries will be 
completed prior to each protocol visit and reviewed for accuracy with the patient at each visit. Pi[INVESTIGATOR_345886].  Optimal adherence is defined as >80% of medication taken. Patients found to be non -adherent with their 
medications will receive additional interventions by [CONTACT_345916] (ie RN phone calls, ext ra visits as needed). If a 
patient demonstrates persistent non -adherence with endocrine therapy, their provider may remove them from the trial (as described in Section 
5.5). 
 10. STUDY CALENDAR  
 10.1 Schedule of Visits
 
54 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
Table 4 summarizes the Study Calendar. Visits should occur within +/ - [ADDRESS_429515] and determine t he reason(s) for 
the missed visit as completely and accurately as possible. Subjects will only be judged as lost to follow -up if they cannot be reached after 
three documented attempts (1  week apart) by [CONTACT_221829]. 
Treatment visits  
Patient will be seen monthly for the first [ADDRESS_429516] of CBC with differential performed : 
• Day 1 and 15 of Cycles 1- 3: Day [ADDRESS_429517] be drawn +/ - 3 days.  
• Every 2 cycles (+/ - 7 days) for Cycles 4- 12 
• Every 3 cycles (+/ - 7 days ) during Year 2 (i.e., C 15D1, C1 8D1, C21D1, C24D1, and End of treatment )  
 
CBCs may be drawn either at the treatment center or at a home clinic when not being seen at the treatment center, for the duration of therapy. This laboratory testing can be done locally with results faxed to the treatment team ; however , treatment should not begin or 
resume until the results have been reviewed .  
 
ECGs will be performed at screening visit, then Day [ADDRESS_429518] to be repeated if the same 
assessments were performed within 7 days of t his visit.   
 Chemistry and Hematol ogy assessments are required 30 days after the completion of protocol therapy or early discontinuation of 
treatment. Labs can be done locally.  
 
 
55 
 
Protocol #: 13-559 
Version Date:   December 16, [ADDRESS_429519] testing performed to assess vitamin B12 levels.  
Table 5. Study Calendar  
 
Pre- 
Study  Treatment phase (2 years tota l)  
Treatment visits will occur every [ADDRESS_429520] 4 cycles of palbociclib  therapy , then 
every 8 weeks through Cycle 12 , then every 12 weeks for year 2.      
4 weeks (28 days) = 1 cycle   Off 
Studyo 
Cycle (C)   C1-3 C1-3 C4  C6 C8 C10 C12 C15 C18 C21 C24  
Day (D)a     -14 to 0  D1 D15 D1 D1 D1 D1 D1 D1 D1 D1 D1  
Informed consent 
(perform within 28 days of 
registration)  X 
-28 to 0             
 
Inclusion/Exclusion criteria X             
Demographic data  X             
Medical/surgical history  X             
Prior medications/  
procedures  
 X             
Pregnancy testb X             
ECOG PSc X X  X X X X X X X X X X 
 12-lead E KGd X X  X X X X X X X X X  
 Physical examination  Xm X  X X X X X X X X X X 
Vital signse  X  X X X X X X X X X X 
Hematologyf X X X X X X X X X X X X X 
Hemoglobin A 1c (HbA 1c)g X C3 only    X X  X X X X  X 
Chemistryh X X  X X X X X X X X X X 
Vitamin B12i X   X          
Whole Blood Samplej  C1 only             
Perform pi[INVESTIGATOR_692]   X  X X X X X X X X X X 
AE evaluationk X X  X X X X X X X X X X 
Concomitant medsl X X  X X X X X X X X X X 
56 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
QOL Surveys  
(See section 9.2)  X Xn   X   X  X   X 
 
a: Assessments on Day 1 of each cycle may be performed within 3 days prior to the start of a new cycle . 
b: Premenopausal patients must have a negative serum or urine pregnancy test.  See section 3.1.7.  
c: See Appendix A for ECOG PS definitions  
d: ECGs will be performed at screening visit, then Day 1 of Cycles 1 -4, then every 2 cycle s through Cycle 12 and then every 3 cycle s for year 2.  ECGs will be performed using 
institutional machines and may be performed up to 72 hours prior to the start of a new cycle.   ECGs are not required on Day 1 of Cycle 1 if performed within 72 
hours before study administration.    
e: Vital signs should include: BP, HR, respi[INVESTIGATOR_697], body temperature and weight   
f:  Hematology assessment consists of CBC with differential. Hematology assessments are not required on Day [ADDRESS_429521] be  drawn  +/- 3 days.  CBCs drawn on non- MD visit days can be drawn at a local lab results submitted to study 
team. See Section 6.2.2 for re -treatment instructions .  
g: Hemoglobin A 1c is performed at pre -study, Day 1 of Cycle 3,  6, 8, 12, 15, 18, 21, and at Off- Study visit.   
h: Chemistry assessment consists of a complete metabolic panel (“chem 12”) . Chemistry assessments are not required on Day [ADDRESS_429522] be drawn +/ - 3 days . See section  6.2.2 for re -treatment instructions .  
i:  B12 assessments are to be performed at baseline, C4D1, and again in any setting of grade [ADDRESS_429523] the B12 assessment performed at their next study visit.  
j: See Sectio n 9 for specimen collection requirements.   
k:  All AEs will be collected from the time the subject initiated therapy until 30 days after discontinuation of study treatme nt. See Section 7 for additional 
information.  
l: Record all prior and concomitant medi cation use (prescription and nonprescription medications as well as transfusions) beginning 30 days before the start of study   
treatment (except record all previous breast cancer treatments)  
m: Baseline Physical Exam may be performed up to 7 days prior to day 1 of Cycle 1  
n: QOL survey to be completed before treatment begins (baseline or day 1 of Cycle 1) and day 1 of Cycle 3.  
o: These assessments will also be conducted upon early discontinuation from the study.  Off study evaluation should be completed within 30 (+/ - 7) days of the last 
day of protocol treatment.  
57 
 
Protocol #: 13-559 
Version Date:  December 16, [ADDRESS_429524]  
 
Tumor r esponse is not the primary endpoint of this trial;  therefore Response Evaluation Criteria 
in Solid Tumors (RECIST) will not be used to aid in measurement of effect.  
 The primary endpoint of the study will be time from initiation of palbociclib to discontinuation of treatment due to toxicity, withdrawal of consent to be treated, or other events related to tolerability. The decision to remove a patient from the study wil l be made by [CONTACT_345917]. All participants who receive at least one dose of study treatment will be evaluable 
for toxicity from the time of their first treatment.  
 Patients who recur, withdraw consent to be followed, or complete 2 years of therapy will be censored at that time point. 
 12. DATA REPORTING / REG ULATORY REQUIREMENTS  
 
Adverse event lists, guidelines, and instructions for AE reporting can be found in Section 7.0 (Adverse Events: List and Reporting Requirements).  
 
12.[ADDRESS_429525], manage, and perform quality checks on the data for this study. 
 
12.1.2 
Responsibility for Data Submission  
 
Investigative sites are responsible for submitting data and/or data forms to the QACT according to the schedule set by [CONTACT_221854].  
 
12.2 Data Safety Monitoring  
 
The DF/HCC Data and Safety Monitoring Committee (DSMC) will review and monitor toxicity and accrual data from this study. The committee is composed of clinical specialists with experience in oncology and who have no direct relationship w ith the study. Information that 
raises any questions about participant safety will be addressed with the Overall PI [INVESTIGATOR_36749].  
 The DSMC will review each protocol up to four times a year or more often if required to review toxicity and accrual data. I nformation to be provided to the committee may include: up- to-date 
participant accrual; current dose level information; DLT information; all grade [ADDRESS_429526] been reported; summary of all deaths occurring with 30 days of intervention for Phase I or II protocols;  for gene therapy protocols, summary of all deaths 
while being treated and during active follow -up; any response information; audit results, and a 
summary provided by [CONTACT_3476]. Other information (e.g. scans, laboratory values) will be provided upon request.  
58 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
 
12.3 Multicenter Guidelines  
 
This protocol will adhere to the policies and requirements of the DF/HCC Multi -Center Data and 
Safety Monitoring Plan.  The specific responsibilities of the Overall PI, Coordinating Center, and Participating Institutions and the procedures for auditing are  presented in Appendix G . 
 
• The Overall PI/Coordinating Center is responsible for distributing all IND Action Letters 
or Sa fety Reports to all participating institutions for submission to their individual IRBs   
 
• Mechanisms will be in place to ensure quality assurance, protocol compliance, and adverse event reporting at each site.  
 
Except in very unusual circumstances, each participating institution will order the study  agent (s) 
directly f rom supplier .  A participating site may order the agent(s) only after the  site has been 
activated  
 
12.[ADDRESS_429527] 2  
more year s of therapy.  
 
13.1 Study Design/Endpoints  
 
 Primary objective:  
- To evaluate the treatment discontinuation rate at 2 years for patients receiving 
combination therapy with endocrine therapy and palbociclib  
 
Secondary objective:  
- To evaluate treat ment discontinuation rates in the subgroups of patients that 
receive AI and tamoxifen- based therapy  
- To describe the safety of extended duration therapy with palbociclib and 
endocrine  therapy  
 
Statistical programming and analyses will be performed using SAS  and other validated statistical 
software as required.  
 A sample size of [ADDRESS_429528] 25% of enrolled patients will not have had exposure to adjuvant chemotherapy.  
59 
 
Protocol #: 13-559 
Version Date:   December 16, [ADDRESS_429529] 6 months of protocol therapy will be replaced. It is expected no more than 5% of the study population would progress on study and need replacement. Subjects  who withdraw after signing the informed consent form 
(ICF) but before receiving study treatment will be replaced.  
 The primary endpoint of the study will be time from initiation of palbociclib to discontinuation of treatment due to toxicity, wit hdrawal of consent to be treated, or other events related to 
tolerability. Patients who recur, withdraw consent to be followed, or complete 2 years of therapy will be censored at that time point.    If the true rate of discontinuation by [CONTACT_345918] 48%  or higher, the treatment duration will be 
considered not feasible and not worthy of further study. If the treatment rate of discontinuation  is 33.3% or less, the treatment duration will be deemed feasible and worthy of further study.  
 The primary analysis of treatment discontinuation will be based on a landmark time analysis at two years, reported with a two- sided 95% confidence interval, and thresholds to an exact 
Binomial test chosen to strictly control the Type I error rate for the evaluable patient popu lation, 
For example, with 128 uncensored patients, the null hypothesis is rejected if 50 or fewer failures 
are observed. Secondary analyses will report the rate of discontinuation at 1 year, and the full survival function will be estimated using the Kaplan -Meier method and a 95% confidence band 
with Greenwood formula for  the standard deviation. 
  
The first interim analyse s for futility is scheduled to occur at the time that 50% of the target 
patients have received treatment , n=80.  The second interim analysis is scheduled to occur at the 
time that 100% of the target patients have ended protocol treatment or received at least 6 months 
of therapy. As a conservative approach to assessing futility for the primary endpoint of 
disco ntinuation by [CONTACT_193957] , the observed proportion of discontinuations among all treated 
patients will be applied to a Beta- Binomial model, and a decision rule  based on there being  less 
than a 5% predicted probability of rejecting the null at the final analy sis.  If a determination of 
futility is made, the study will cease and treatment duration of two years  will be considered not 
feasible.  Fu rther, p-values from the primary analysis will not be downwardly corrected to adjust 
for the interim futility analyse s. Results of the interim analysis will be made available for 
presentation after final analysis is complete.  
 
Within the subgroups of patients that receive an AI or tamoxifen for endocrine therapy, the Kaplan -Meier method and a 95% confidence band will be used to estimate survival functions.  
 
13.2 Sample Size/Accrual Rate  
 
Using a one -sided alpha = 0.025, there will be greater than 90% power to reject the null 
hypothesis in favor of feasibility with 128 subjects. A total sample size of 160 patients is planned 
to account for a censoring rate of 20% for the primary endpoint.   
 
Accrual is anticipated to be approximately 10 patients per month, such that there would be 18 
months of patient accession, and 24 months of follow -up until the final analysis.  
 
60 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
 
 
Accrual Targets  
Ethnic Category  Sex/Gender  
Females   Males   Total  
Hispanic or Latino  16 + 0 = 16 
Not Hispanic or Latino  144 + 0 = 144 
Ethnic Category: Total of all subjects  160 (A1)  + 0 (B1) = 160 (C1) 
Racial Category  
American Indian or Alaskan Native  2 + 0 = 2 
Asian  16 + 0 = 16 
Black or African American  16 + 0 = 16 
Native Hawaiian or other Pacific 
Islander  2 + 0 = 2 
White  124 + 0 = 124 
Racial Category: Total of all subjects  160 (A2)  + 0 (B2) = 160 (C2) 
 (A1 = A2)   (B1 = B2)   (C1 = C2)  
 
13.3 Analysis of Secondary Endpoint: Safety of Extended Duration Therapy with 
Palbociclib and Endocrine Therapy  
 
All patients who receive at least one dose of the study regimens will be included in the 
assessment of adverse events (full analysis population). Adverse event information for the two 
cohorts will be combined. Safety data that will be evaluated include AEs, clinical laboratory 
results, vital signs, and ECGs. Abnormal laboratory values will be flagged.  
Adverse event information will be collected from the time the  subject signs the ICF until 
resolution or for [ADDRESS_429530]’s last study visit, whichever comes first. Treatment -
emergent AEs (TEAEs) will be analyzed. Adverse events will be regarded as TEAEs if they 
started on or after the date and time of administration of the first dose of study treatment or if they were present before the administration of the first dose of study treatment and increased in severity during the study. Treatment -emergent peripheral neuropathy will be followed until 
resolution  or until the start of another anticancer therapy post treatment, whichever occurs first.  
Adverse events will be graded using CTCAE v 4.0 (
http://ctep.cancer.gov/prot ocolDevelopment/electronic_applications/ctc.htm ; Appendix C.)  
Investigators will collect all CTCAE grades for all AEs (to assess both increasing and decreasing severity). Events will be summarized by [CONTACT_7237].  
The incidence of TEAEs and re latedness to study treatment will be summarized. Although an 
adverse event may be reported more than once for a subject, that subject will be counted only one time in the incidence count for that adverse event term by [CONTACT_221839] (in the summar y by [CONTACT_3229]) and by [CONTACT_221840] (in the 
summary by [CONTACT_221841]). 
Continual assessment of toxicity is planned, including specifically a monthly assessment of the 
total number of cases of Grade 3 or 4 (ANC<1000/mm3) febrile neutropenia. Events are 
61 
 
Protocol #: 13-559 
Version Date:   December 16, [ADDRESS_429531] a 90% chance 
of triggering a review if the true risk of febrile neutropenia is 6.5% and less than a 10% chance 
of triggering a review if the true risk is 2.0%.  Further, a 10% rate of all neutropenia AEs will be 
used as a non -binding threshold with the monthly review to inform decisions  on dose and 
schedule . 
 
 
13.[ADDRESS_429532] one dose of study medication will be assessed for the primary endpoint (time from initiation of palbociclib to discontinuation of treatment due to toxicity, withdrawal of consent to be treated, or other events related to tolerability).  
 
13.[ADDRESS_429533].   We anticipate that 80 patients will be enrolled after the amendment to include the QOL objective, and that 85% will provide complete informatio n for paired tests. Under Gaussian 
assumption, there will be 90% power to detect a change from baseline of 0.36 standardized units using a two- sided alpha = 0.05. Scores will also be summarized graphically over the repeated 
assessments, and linear mixed ef fects models will be used to explore a QoL response profile over 
the course of treatment. The impact of missing data will be assessed using graphical methods to explore the patterns of missing assessments, and baseline patient/disease characteristics will be compared between patients who do and do not provide complete QOL data. Primary analyses will be performed using all available data . 
 
 
62 
 
Protocol #: 13-559 
Version Date:   December 16, [ADDRESS_429534] Cancer Symposium.  Results 
of the formal interim analysis will be made available for presentation after analysis is complete. A full report of the outcomes will be made public no later than two (2) years after the end of data collection.  
  
63 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
15. REFEREN CES  
 
 1. Baselga J, Campone M, Pi[INVESTIGATOR_94899] M, et al: Everolimus in postmenopausal 
hormone -receptor -positive advanced breast cancer. The New England journal of medicine 
366:520- 9, 2012 
 2. Bachelot T, Bourgier C, Cropet C, et al: Randomized phase II trial of 
everolimus in combination with tamoxifen in patients with hormone receptor -positive, human 
epi[INVESTIGATOR_3506] [ADDRESS_429535] cancer with prior exposure to 
aromatase inhibitors: a GINECO study. Journal of clinic al oncology : official journal of the 
American Society of Clinical Oncology 30:2718- 24, 2012 
 3. Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of 
G1-phase progression. Genes & development 13:1501- 12, 1999 
 4. van den Heuvel S, Harl ow E: Distinct roles for cyclin -dependent kinases 
in cell cycle control. Science 262:2050- 4, 1993 
 5. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 
81:323- 30, 1995 
 6. Harper JW, Adami GR, Wei N, et al: The p21 Cdk- interacting protein 
Cip1 is a potent inhibitor of G1 cyclin- dependent kinases. Cell 75:805- 16, 1993 
 7. Koff A, Ohtsuki M, Polyak K, et al: Negative regulation of G1 in 
mammalian cells: inhibition of cyclin E -dependent kinase by [CONTACT_4722] -beta. Science 260:536- 9, 1993 
 8. Polyak K, Kato JY, Solomon MJ, et al: p27Kip1, a cyclin- Cdk inhibitor, 
links transforming growth factor -beta and contact [CONTACT_4723]. Genes & 
development 8:9- 22, 1994 
 9. Sherr CJ: D -type cyclins. Trends in biochemical sciences 20:187 -90, 1995 
 10. Toyoshima H, Hunter T: p27, a novel inhibitor of G1 cyclin- Cdk protein 
kinase activity, is related to p21. Cell 78:67- 74, [ADDRESS_429536] L, et al: Retinoblastoma- protein -dependent 
cell-cycle inhibition by [CONTACT_4724] p16. Nature 375:503- 6, 1995 
 12. Medema RH, Herrera RE, Lam F, et al: Growth suppression by p16ink4 
requires functional retinoblastoma protein. Proceedings of the National Academy of Sciences of the [LOCATION_002] of America 92:6289 -93, 1995 
 13. Butt AJ, McNeil CM, Musgrove EA, et al: Downstream targets of growth 
factor and oestrogen signalling and endocrine resistance: the potential roles of c- Myc, cyclin D1 
and cyclin E. Endocrine -related cancer [ADDRESS_429537] 1:S47- 59, 2005 
 14. Altucci L, Addeo R, Cicatiello L,  et al: Estrogen induces early and timed 
activation of cyclin -dependent kinases 4, 5, and 6 and increases cyclin messenger ribonucleic 
acid expression in rat uterus. Endocrinology 138:978- 84, 1997 
 15. Geum D, Sun W, Paik SK, et al: Estrogen- induced cyclin D1 and D3 gene 
expressions during mouse uterine cell proliferation in vivo: differential induction mechanism of cyclin D1 and D3. Molecular reproduction and development 46:450- 8, 1997 
 16. Said TK, Conneely OM, Medina D, et al: Progesterone, in addition t o 
estrogen, induces cyclin D1 expression in the murine mammary epi[INVESTIGATOR_1231], in vivo. Endocrinology 138:3933- 9, [ADDRESS_429538] JW: Progesterone inhibits estrogen- induced cyclin D1 
and cdk4 nuclear translocation, cyclin E - and cyclin A -cdk2 ki nase activation, and cell 
proliferation in uterine epi[INVESTIGATOR_4604]. Molecular and cellular biology 19:2251 -64, 1999 
 18. Altucci L, Addeo R, Cicatiello L, et al: 17beta -Estradiol induces cyclin D1 
64 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
gene transcription, p36D1- p34cdk4 complex activati on and p105Rb phosphorylation during 
mitogenic stimulation of G(1) -arrested human breast cancer cells. Oncogene 12:2315- 24, 1996 
 19. Foster JS, Wimalasena J: Estrogen regulates activity of cyclin -dependent 
kinases and retinoblastoma protein phosphorylation in breast cancer cells. Molecular 
endocrinology 10:488- 98, 1996 
 20. Planas- Silva MD, Weinberg RA: Estrogen- dependent cyclin E -cdk2 
activation through p21 redistribution. Molecular and cellular biology 17:4059- 69, 1997 
 21. Prall OW, Sarcevic B, Musgrove EA, et al: Estrogen -induced activation of 
Cdk4 and Cdk2 during G1- S phase progression is accompanied by [CONTACT_4720] D1 
expression and decreased cyclin -dependent kinase inhibitor association with cyclin E -Cdk2. The 
Journal of biological chemistry 272: [ZIP_CODE]- 94, 1997 
 22. Lukas J, Bartkova J, Bartek J: Convergence of mitogenic signalling 
cascades from diverse classes of receptors at the cyclin D -cyclin -dependent kinase -pRb-
controlled G1 checkpoint. Molecular and cellular biology 16:6917- 25, 1996 
 23. Watts CK, Brady A, Sarcevic B, et al: Antiestrogen inhibition of cell cycle 
progression in breast cancer cells in associated with inhibition of cyclin -dependent kinase 
activity and decreased retinoblastoma protein phosphorylation. Molecular endocrinology 9:1804-13, 1995  24. Thangavel C, Dean JL, Ertel A, et al: Therapeutically activating RB: 
reestablishing cell cycle control in endocrine therapy -resistant breast cancer. Endocrine- related 
cancer 18:333 -45, 2011 
 25. Yu Q, Sicinska E, Geng Y, et al: Requirement  for CDK4 kinase function 
in breast cancer. Cancer cell 9:23 -32, 2006 
 26. Konecny GE, Winterhoff B, Kolarova T, et al: Expression of p16 and 
retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Clinical cancer 
research : an official journal of the American Association for Cancer Research 17:1591- 602, 
2011  27. Fry DW, Harvey PJ, Keller PR, et al: Specific inhibition of cyclin -
dependent kinase 4/6 by [CONTACT_4002] 0332991 and associated antitumor activity in human tumor xenografts. Molecular cancer therapeutics 3:1427 -38, 2004 
 28. Cen L, Carlson BL, Schroeder MA, et al: p16- Cdk4 -Rb axis controls 
sensitivity to a cyclin -dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. 
Neuro -oncology 14:870- 81, 2012 
 29. Finn RS, Dering J, Conklin D, et al: PD 0332991, a selective cyclin D 
kinase 4/[ADDRESS_429539] cancer research : BCR 11:R77, 2009  
 30. FINAL REPORT, Spons or Reference No. 12LJ025, A 15- Week Toxicity 
Study of PD -0332991 by [CONTACT_345919] a 4- Week Recovery Period, 
SPONSOR: [COMPANY_007] Worldwide Research and Development Drug Safety Research & Development.   31. DeMichele A, Sanders Clark A,  Heitjan D, et al: A phase II trial of an oral 
CDK 4/[ADDRESS_429540]:abstr 519, 2013  32. Slamon DJ, Hurvitz SA, Applebaum S, et al: Phase I study of PD 
0332991, cyclin -D kinase (CDK) 4/[ADDRESS_429541] cancer. J Clin Oncol 28:abstr 
3060, 2010 
65 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
 33. Finn RS, Crown JP, Boer K, et al: Preliminary results of a randomized 
phase 2 study of PD 0332991, a cycl in-dependent kinase (CDK) 4/[ADDRESS_429542]- line treatment of patients (pts) with post- menopausal, ER+, HER2-
negative (HER -) advanced breast cancer. Cancer Res 71:P1 -17-05, 2011 
 34. Davies C, Pan H, Godwin J, et al: Long- term effects of continuing 
adjuvant tamoxifen to [ADDRESS_429543] cancer: ATLAS, a randomised trial. Lancet 381:805- 16, 2013 
 35. Flaherty KT, Lorusso PM, Demichele A, et al: Phase I, dose -escalation 
trial of the oral cyclin -dependent kinase 4/6 inhibitor PD 0332991, administered using a 21- day 
schedule in patients with advanced cancer. Clinical cancer research : an official journal of the 
American Association for Cancer Research 18 :568-76, 2012 
   
66 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
APPENDIX A: EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG ) 
PERFORMANCE STATUS C RITERIA  
 
Description  Grade  
Fully active, able to carry on all pre -disease performance 
without restriction.  0 
Restricted in physically strenuous activity, but ambulatory 
and able to carry out work of a light or sedentary nature, 
i.e., light house work, office work. 1 
Ambulatory and capable of all self -care but unable to carry 
out any work activities.  Up and about more than 50% of 
waking hours. 2 
Capable of only limited self -care, confined to bed or chair 
more than 50% of waking hours.  3 
Completely disabled.  Cannot carry on any self -care.  
Totally confined to bed or chair.  4 
 
     
 
  
  
67 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
APPENDIX B: CYP3A INDUCERS/INHIBITORS AND INFORMATION ON P OSSIBLE 
DRUG INTERACTIONS  
 
Medications that strongly inhibit CYP3A:  
Amprenavir  
Atazanavir  
Boceprevir  
Clarithromycin  
Conivaptan  
Delavirdine  
Diltiazem  
Erythromycin 
Fosamprenavir  
Indinavir  
Itraconazole  
Ketoconazole  
Lopi[INVESTIGATOR_345887], grapefruit juice, or any product containing grapefruit  
 
Medications that strongly induce CYP3A:  
Carbamazepin e 
Felbamate 
Nevirapi[INVESTIGATOR_345888]. John’s wort  
 
Medications that moderately  induce CYP3A:  
Bosntan 
Efavirenz  
Etravine  
Modafinil  
68 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
Nafcillin  
 
 
 
    
69 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
APPENDIX C: COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS 
(VERSION 4.0)  
 
Cancer Therapy Evaluation Program, NCI CTCAE v 4.0. Available from  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev 4.pdf . 
 
            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
              
70 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
 
APPENDIX D: 13- 559 STUDY PARTICIPANT SE LF-ADMINISTERED DRUG DI ARY  
 
PATIENT INSTRUCTIONS:  
 
Take your medications exactly as prescribed by [CONTACT_4904].  See the next page for specific doses for each 
medication that you are taking on this study.  
• Keep Palbociclib capsules in the bottle (s) provided and do not transfer them  to any other container. 
Store at room temperature.  
• Palbociclib should be taken by [CONTACT_345920]. Palbociclib should be taken with food.  
o During Cycles 1, [ADDRESS_429544] blood work done on Day 15. Please do not take the next 
day’s drug (Day 16) until a  provider calls yo u to discuss the results.  
• Capsules must be swallowed whole . Do not soak capsules or empt y contents  into any food or drink.  
• If you vomit after taking Palbociclib, do NOT take another dose . Please note any vomiting in the 
Comments  section of the diary on the next page.  
• If a dose  is missed and it is less than [ADDRESS_429545] “0” for Number Taken  on the next page.  
• If you accidentally take an  extra dose during a day skip the next day’s dose  and record the extra dose 
on the next page.   
 
 
      FOR CLINIC USE ONLY:  
• Give patient all 4 pages of Drug Diary 
stapled together.  Provide one diary per 
cycle (28 days).  
• Complete patient identifiers and medical 
team contact [CONTACT_345921] 2- 4.  
• Complete date of last Palbociclib dose n 
page 2 and the name [CONTACT_345926] 3.  
• When patient returns pi[INVESTIGATOR_345889] a Palbociclib pi[INVESTIGATOR_345890] .  Staff Initials:  
  
Date Dispensed:  
  Date Returned:  
  
# Palbociclib capsules 
dispensed:   #  Palbociclib capsules 
returned:  
#  Palbociclib capsules that should have been taken:  
  
Discrepancy Notes:  
  
  
71 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
13-559 STUDY PARTICIPANT SELF -ADMINISTERED DIARY  
 
Participant Name : ___________________________________                         Cycle #: ______  
Your Doctor  ____________________________    Phone ____________________  
Your N urse _____________________________   Phone ____________________ 
 
PALBOCICLIB (Cycles 1 -3) 
STUDY DRUG INSTRUCTIONS : Take one Palbociclib capsule on Days 1 – 21. Record the dose of each 
medication on the chart to the right after taking each day.  
 
 Date Time  Number of 
Palbociclib 
Capsules Taken  Comments  
Ex: 6/1/2009        8 : 15     AM    PM 1 Vomited 1 hour later  
Day 1             :          AM    PM     
Day 2             :          AM    PM     
Day 3             :          AM    PM     
Day 4             :          AM    PM     
Day 5             :          AM    PM     
Day 6             :          AM    PM     
Day 7             :          AM    PM     
Day 8             :          AM    PM     
Day 9             :          AM    PM     
Day 10             :          AM    PM     
Day 11             :          AM    PM     
Day 12             :          AM    PM     
Day 13             :          AM    PM     
Day 14             :          AM    PM     
Day 15             :          AM    PM 
   
During Cycles 1, 2, and 3 only: Remember to have your lab work done on Day 15.  Make sure you speak with your 
provider  before taking the capsule on Day 16.  
Day 16             :          AM    PM     
Day 17             :          AM    PM     
Day 18             :          AM    PM     
Day 19             :          AM    PM     
Day 20             :          AM    PM     
Day 21             :          AM    PM     
 
Do not take any Palbociclib after: _____/_____/_________   
 
Patient Signature: _______________________________________   Date: _____/_____/_________
72 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
 
 
13-559 STUDY PARTICIPANT SELF -ADMINISTERED DIARY  
 
Participant Name: ___________________________________                         Cycle #: ______  
Your Doctor  ____________________________    Phone ____________________  
Your N urse _____________________________   Phone ____________________ 
 
PALBOCICLIB (Cycle 4 and all remaining cycles ) 
STUDY DRUG INSTRUCTIONS : Take one Palbociclib capsule on Days 1 – 21. Record the dose of each 
medication on the chart to the right after taking each day.  
 
 Date Time  Number of 
Palbociclib 
Capsules Taken  Comments  
Ex: 6/1/2009        8 : 15     AM    PM 1 Vomited 1 hour later  
Day 1             :          AM    PM     
Day 2             :          AM    PM     
Day 3             :          AM    PM     
Day 4             :          AM    PM     
Day 5             :          AM    PM     
Day 6             :          AM    PM     
Day 7             :          AM    PM     
Day 8             :          AM    PM     
Day 9             :          AM    PM     
Day 10             :          AM    PM     
Day 11             :          AM    PM     
Day 12             :          AM    PM     
Day 13             :          AM    PM     
Day 14             :          AM    PM     
Day 15             :          AM    PM 
   
Day 16             :          AM    PM     
Day 17             :          AM    PM     
Day 18             :          AM    PM     
Day 19             :          AM    PM     
Day 20             :          AM    PM     
Day 21             :          AM    PM     
 
Do not take any Palbociclib after: _____/_____/_________    Patient Signature: _______________________________________   Date: _____/_____/_________
73 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
Participant Name: ___________________________________                         Cycle #: ______  
 
ENDOCRINE THERAPY  
STUDY DRUG INSTRUCTIONS : Take one _____________________ on Days 1 – 28. Record the dose of 
each medication on the chart to the right after taking each day.  
 Date  Time  Number  of Pi[INVESTIGATOR_345891]: 6/1/2009        8 : 15     AM    PM 1 Vomited 1 hour later  
Day 1             :          AM    PM     
Day 2             :          AM    PM     
Day 3             :          AM    PM     
Day 4             :          AM    PM     
Day 5             :          AM    PM     
Day 6             :          AM    PM     
Day 7             :          AM    PM     
Day 8             :          AM    PM     
Day 9             :          AM    PM     
Day 10             :          AM    PM     
Day 11             :          AM    PM     
Day 12             :          AM    PM     
Day 13             :          AM    PM     
Day 14             :          AM    PM     
Day 15             :          AM    PM     
Day 16             :          AM    PM     
Day 17             :          AM    PM     
Day 18             :          AM    PM     
Day 19             :          AM    PM     
Day 20             :          AM    PM     
Day 21             :          AM    PM     
Day 2 2 
          :          AM    PM 
  Day 2 3 
          :          AM    PM 
  Day 2 4 
          :          AM    PM 
  Day 25 
          :          AM    PM 
  Day 2 6 
          :          AM    PM 
  Day 2 7 
          :          AM    PM 
  Day 2 8 
          :          AM    PM 
   
 Patient Signature: _______________________________________   Date: _____/_____/_________
74 
 
Protocol #: 13-559 
Version Date:  December 16, 2016  
 
13-559 S TUDY PARTICIPANT SELF -ADMINISTERED DRUG DIARY  
 
 
Participant Name: ___________________________________                         Cycle #: ______  
 
 
OTHER MEDICATIONS TAKEN: Please list any daily medications (prescribed or otherwise) that you take. 
Use one line per drug and indicate the start and stop dates under the "Date(s) Taken" section (i.e., 6/2/09 -  
6/5/09).     
 
Drug Name  [CONTACT_345927]/SIDE EFFECTS: Please record any side effects experienced during this cycle. Include the date the particular symptom started and when it ended.       
 Symptom    Start  Date  End Date  
        
        
        
        
        
        
        
        
        
        
   
75 
 
Protocol #: 13-559 
Version Date:  December 16, 2016  
 
APPENDIX E : 13-559 SPECIMEN REQUISITION FORM  
 
Complete this form and include with the specimen shipment .  Label ALL materials with participant initials, 
DFCI participant study ID, and the date the specimen was obtained.  
 
Ship specimen(s) at ambient temperature  to:   
Dana -Farber Cancer Institute  
  
   
 __________________________________________________________________________________________ 
 
Specimen Information  
Participant Initials (FML): __________     DFCI Participant Study ID Number: _____________      
Time period:   Pre-treatment Cycle 1 Day 1     Date specimen(s) shipped: __________________ 
  
Specimen Type  
(indicate inclusion in shipment by [CONTACT_345922])  Quantity 
submitted  Date specimen collected  
  10 mL Whole Blood in lavender top (EDTA) tube    
 Other, specify:   
 
Responsible contact: ___________________________ ____                          
Email: ___________________________________________  
Phone number: ____________________________________  
Site: _____________________________________________  
   
76 
 

Protocol #: 13-559 
Version Date:   December 16, 2016  
 
APPENDIX F : LIST OF DRUGS KNOW N TO PREDISPOSE TO TORSADE DE POINTES  
Generic Name  [CONTACT_4743](s)  
Amiodarone  Cordarone®, Pacerone® 
Arsenic trioxide  Trisenox® 
Astemizole  Hismanal® 
Azithromycin  Zithromax® 
Bepridil  Vascor® 
Chloroquine  Aralen® 
Chlorpromazine  Thorazine® 
Cisapride  Propulsid® 
Clarithromycin  Biaxin® 
Disopyramide  Norpace® 
Dofetilide  Tikosyn® 
Domperidone  Motilium® 
Droperidol  Inapsine® 
Erythromycin  Erythrocin®, E.E.S.® 
Flecainide  Tambocor® 
Halofantrine  Halfan® 
Haloperidol  Haldol® 
Ibutilide  Corvert® 
Levomethadyl  Orlaam® 
Mesoridazine  Serentil® 
Methadone  Dolophine®, Methadose® 
Moxifloxacin  Avelox® 
Pentamidine  Pentam®, NebuPent® 
Pi[INVESTIGATOR_31930]® 
Probucol  Lorelco® 
Procainamide  Pronestyl®, Procan® 
Quinidine  Cardioquin®, Quinaglute® 
Sotalol  Betapace® 
Sparfloxacin  Zagam® 
Terfenadine  Seldane® 
Thioridazine  Mellaril® 
Vandetanib  Caprelsa® 
 
  
77 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
APPENDIX G : DANA- FARBER/HARVARD CANCER CENTER MULTI -CENTER DATA AND 
SAFETY MONITORING PLAN  
 
 
 
DFCI IRB Protocol #: 13-559 
 
 
 
 
 
 
  
 
 
 
 
  
 
  
 
  
 
  
 
 
 
  
 
  
 
 
 
  
78 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
TABLE OF CONTENTS  
1.0 INTRODUCTION  .................................................................................................................59 
1.1 Purpose  ...................................................................................................................59 
1.2 Multi -Center Data and Safety Monitoring Plan Definitions  ..................................59 
2.0 GENERAL ROLES AND RESPONSIBILIT IES .................................................................60 
2.1 DF/HCC Sponsor  ...................................................................................................60 
2.2 Coordinating Center  ...............................................................................................60 
2.3 DF/HCC Quality Assurance Office for Clinical Trials (QACT) ...........................61 
2.4 Participating Institution  ..........................................................................................61 
3.0 DF/HCC REQUIREMENTS FOR MULTI -CENTER PROTOCOLS  .................................62 
3.1 Protocol Distribution  ..............................................................................................62 
3.2 Protocol Revisions and Closures  ...........................................................................62 
3.3 Informed Consent Requirements  ...........................................................................62 
3.4 IRB Documentation  ...............................................................................................63 
3.5 IRB Re -Approval  ...................................................................................................63 
3.6 Participant Confidentiality and Authorization Statement ......................................63 
3.7 DF/HCC Multi -Center Protocol Registration Policy  .............................................64 
3.7.1 Participant Registration and Randomization  .........................................................64 
3.7.2 Initiation of Therapy  ..............................................................................................64 
3.7.3 Eligibility Exceptions  .............................................................................................64 
3.7.4 Verification of Registration, Dose Levels, and Arm Designation .........................64 
3.8 DF/HCC Protocol Case Number  ............................................................................64 
3.9 Protocol Deviations, Exceptions and Violations  ...................................................64 
3.9.1 Definitions ..............................................................................................................65 
3.9.2 Reporting Procedures  .............................................................................................65 
3.10 Safety Assessments and Toxicity Monitoring  .......................................................65 
3.10.1 Guidelines for Reporting Serious Adverse Events  ................................................87 
3.10.2 Guidelines for Processing IND Safety Reports  .....................................................66 
3.11 Data Management  ..................................................................................................66 
3.11.1 Data Forms R eview ................................................................................................66 
4.0 REQUISITIONING STUDY DRUG ....................................................................................67 
5.0 MONITORING: QUALITY CONTROL  ..............................................................................67 
5.1 Ongoing Monitoring of Protocol Compliance  .......................................................67 
5.2 Evaluation of Participating Institution Performance  ..............................................68 
5.2.1 Monitoring Reports  ................................................................................................68 
6.0 AUDITING: QUALITY ASSURANCE  ...............................................................................68 
6.1 NCI Sponsored Trials  ............................................................................................69 
6.2 DF/HCC Sponsored Trials  .....................................................................................69 
6.3 Participating Institution  ..........................................................................................69 
6.4 DF/HCC Sponsor and Coordinating Center  ..........................................................[ADDRESS_429546] Perform ance ....................................................................................69 
6.5.1 Corrective Actions  .................................................................................................69 
 
  
79 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
 
1.0 INTRODUCTION  
 
The Dana -Farber/Harvard Cancer Center Multi -Center Data and Safety Monitoring Plan (DF/HCC 
DSMP) outlines the procedures for conducting  a DF/HCC Multi -Center research protocol. The DF/HCC 
DSMP should serve as a reference for any sites external to DF/HCC that will be participating in the 
research protocol.  
 
1.1 Purpose  
 
To establish standards that will ensure that a Dana- Farber/Harvard Cancer Center Multi -Center study will 
comply with Federal Regulations, Health Insurance Portability and Accountability Act (HIPAA) requirements and applicable DF/HCC Standard Operating Proc edures. .        
 
1.2 Multi -Center Data and Safety Monitoring Plan Definitions  
 
DF/HCC Multi -center Protocol :  A research study in which one  or more outside institutions are 
collaborating with Dana -Farber/Harvard Cancer Center where  a DF/HCC investigator is the sponsor. 
DF/HCC includes Dana -Farber/Partners Cancer Care (DF/PCC) Network Clinical Trial Affiliates.  
 Lead Institution:  One of the  Dana -Farber/Harvard Cancer Center consortium members (Dana -Farber 
Cancer Institute (DFCI), [LOCATION_005] General Hospi[INVESTIGATOR_307] (MGH), Beth Israel Deaconess Medical Center (BIDMC), Children’s Hospi[INVESTIGATOR_7724] (CHB), Brigham and Women’s Hospi[INVESTIGATOR_307] (BWH)) responsible  for 
the coordination, development, submission, and approval of a protocol as well as its subsequent amendments per the DFCI IRB and applicable regulatory guidelines (CTEP, Food and Drug 
Administration (FDA), Office of Biotechnology Activities (OBA) etc.).   The Lead Institution is typi[INVESTIGATOR_345892]/HCC Sponsor. The Lead Institution also typi[INVESTIGATOR_143001]/HCC Multi- Center Protocol.   
 DF/HCC Sponsor:  The  person sponsoring the submitted Multi -Center protocol.  Within DF/HCC, this 
person is the Overall Principal Investigator [INVESTIGATOR_345893], management and conduct of the protocol at all research locations. In applicable protocols, the DF/HCC Sponsor will serve as the single liaison with any regulatory agencies (i.e. CTEP Protocol and Information Office (PIO), FDA, OBA etc.). The DF/HCC Sponsor has ultimate authority over the protocol and is responsible for the conduct of the study at DF/HCC and all Participating Institutions. In most cases the DF/HCC Sponsor is the same person as the DF/HCC Principal Investigator; however, both roles can be filled by [CONTACT_57945].  
 
Participating Institution:  An institution that is outside the DF/HCC and DF/PCC consortium that is collaborating with DF/HCC on a protocol where the sponsor is a DF/HCC Investigator.  The Participating Institution acknowledges the DF/HCC Sponsor as having the ultimate authority and responsibility for the overall conduct of the study.    
 
 Coordinating Center: The entity ( i.e. Lead Institution, Medical Monitor, Contract Research 
Organization (CRO), etc) that provides administrative support to the DF/HCC Sponsor in order that he/she may fulfill the responsibilities outlined in the protocol document and DSMP, and as specified in 
applicable regulatory guidelines (i.e. CTEP Multi -Center Guidelines). In general, the Lead Institution is 
80 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
the Coordinating Center for the DF/HCC Multi- Center Protocol. Should the DF/HCC Sponsor decide to 
use a CRO, the CRO will be deemed the Coordinati ng Center.   
 
DF/HCC Quality Assurance Office for Clinical Trials: A unit within DF/HCC developed to computerize and manage data, and to provide a Quality Control and Quality Assurance function for DF/HCC trials.   
 2.0 GENERAL ROLES AND RESPONSIBILITIES  
For DF/HCC Multi- Center Protocols, the DF/HCC Sponsor, the Coordinating Center, and the 
Participating Institutions are expected to adhere to the following general responsibilities:  
 
2.1 DF/HCC Sponsor  
 The DF/HCC Sponsor , Erica Mayer, MD,  will accept responsi bility for all aspects of conducting a 
DF/HCC Multi -Center protocol which includes but is not limited to:  
• Oversee the coordination, development, submission, and approval of the protocol as well as 
subsequent amendments.  
• Ensure that the investigators, study team members, and Participating Institutions are qualified and 
appropriately resourced to conduct the protocol.   
• Submit the Multi -Center Data and Safety Monitoring Plan as an appendix to the protocol.  
• Assure all Participating Institutions are using the correct version of the protocol.  
• Ensure that each participating investigator and study team receives adequate protocol training and/or a Site Initiation Visit prior to enrolling participants and throughout trial’s c onduct as 
needed.  
• Ensure the protocol will be provided to each participating site in a language understandable to all 
site personnel when English is not the primary language.  
• Monitor progress and overall conduct of the study at all Participating Instituti ons.  
• Ensure all DFCI Institutional Review Board (IRB), DF/HCC and other applicable (e.g.,  FDA) reporting requirements are met.  
• Review data and maintain timely submission of data for study analysis.  
• Act as the single liaison with the FDA (investigator- held IND trials).  
• Ensure compliance with all requirements as set forth in the Code of Federal Regulations, applicable DF/HCC requirements, HIPAA requirements, and the approved protocol.  
• Commit to the provision that the protocol will not be rewritten or modi fied by [CONTACT_254710]/HCC Sponsor. 
• Identify and qualify Participating Institutions and obtain accrual commitments prior to extending 
the protocol to that site.  
• Monitor accrual and address Participating Institutions that are not meeting their ac crual 
requirements  
  
2.2 Coordinating Center  
 
The Coordinating Center will assume the following general responsibilities:  
• Assist in protocol development  
• Maintain copi[INVESTIGATOR_143002] (IRB) approvals from 
all Participating Institutions.  
81 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
• Maintain FDA correspondence, as applicable.  
• Maintain updated roster of participants.  
• Verify eligibility.  
• Oversee the data collection process from Participating Institutions.  
• Maintain documentation of Serious Adverse Event (SAE)  reports submitted by [CONTACT_345923]/HCC Sponsor for timely review.   
• Distribute adverse events reported to the DF/HCC Sponsor that fall under the DFCI IRB Adverse 
Event Reporting Policy to all participating investigators.  
• Prov ide Participating Institutions with information regarding DF/HCC requirements that they will 
be expected to comply with.    
• Monitor Participating Institutions either by [INVESTIGATOR_2394] -site or virtual monitoring.  
• Maintain Regulatory documents of all Participating Insti tutions.  
• Conduct regular communications with all Participating Institutions (conference calls, emails, etc).  
• Maintain documentation of all communications.  
• Ensure that each Participating Institution has the appropriate assurance on file with the Office of  
Human Research Protection (OHRP).     
 
2.3 DF/HCC Quality Assurance Office for Clinical Trials (QACT)  
 
In addition to the Coordinating Center, the DF/HCC QACT provides the following support services to assist the DF/HCC Sponsor:  
• Develop protocol specific case report forms (CRF/eCRFS).  
• QA/QC data of protocol specific CRFs.  
• Provide a central participant registration, which includes review of consent and eligibility.  
• Provide auditing services (funding and QACT approval required).  
 
2.4 Participating Institution  
 Each Participating Institution is expected to comply with all applicable Federal Regulations and DF/HCC requirements, the protocol and HIPAA requirements. All Participating Institutions will provide a list of personnel assigned to the role for oversight of  data management at their site to the Coordinating Center.  
 
The general responsibilities for each Participating Institution are as follows: 
• Commit to the accrual of participants to the protocol.  
• Submit protocol and/or amendments to their local IRB.  
• Maintain a regulatory binder in accordance with DF/HCC requirements. 
• Provide the Coordinating Center with regulatory documents as requested.  
• Participate in protocol training prior to enrolling participants and throughout the trial as needed 
(i.e. teleconferences).  
• Update Coordinating Center with research staff changes on a timely basis.  
• Register participants through the Coordinating Center.  
• Submit source documents, research records, and CRFs per protocol specific submission guidelines to the Coordinating Center. 
• Submit Serious Adverse Event (SAE) reports to local IRB per local requirements and to the Coordinating Center, in accordance with DF/HCC requirements.  
• Submit protocol deviations and violations to local IRB per local requirements and to the DF/HCC 
Sponsor  in accordance with DF/HCC requirements. 
82 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
• Secure and store investigational agents and/or other protocol mandated drugs per federal 
guidelines and protocol requirements. 
• Have office space, office equipment, and internet access that meet HIPAA standards.  
• For protocols using investigational agents, the Participating Institution will order their own 
investigational agents regardless of the supplier (i.e. National Cancer Institute (NCI), 
pharmaceutical company).  
 
3.0 DF/HCC REQUIREMENTS FOR MULTI -CENTER PROTOCOLS  
  
The following section will clarify DF/HCC requirements and further detail the expectations for participating 
in a DF/HCC Multi -Center protocol.  
 
3.1 Protocol Distribution  
 The Coordinating Center will distribute the final DFCI IRB approved protocol and any subsequent amended protocols to all Participating Institutions.    
 
3.2 Protocol Revisions and Closures  
 The Participating Institutions will receive notification of protocol revisions and closures from the Coordinating Center.  It is the individual Participating Institution’s responsibility to notify its IRB of these revisions.  
 
• Non life -threatening revisions:  Participating Institutions will receive written notification of 
protocol revisions regarding non life -threatening events from the Coordinating Center. Non- life-
threatening protocol revisions must be IRB approved and implemented within 90 days from receipt of the notification.  
 
• Revisions for life- threatening causes:  Participating Institutions will receive immediate 
notification from the Coordinating Center concerning protocol revisions required to protect lives 
with follow -up by [CONTACT_6791], mail, e -mail, etc.  Life -threatening protocol revisions will be implemented 
immediat ely followed by [CONTACT_143066]. 
 
• Protocol closures and temporary holds:  Participating Institutions will receive notification of 
protocol closures and temporary holds from the Coordinating Center. Closures and holds will be 
effective immediately.  In addition, the Coordinating Center, will update the Participating 
Institutions on an ongoing basis about protocol accrual data so that they will be aware of imminent protocol closures.  
 
3.3 Informed Consent Requirements  
 The DF/HCC approved informed consent  document will serve as a template for the informed consent for 
Participating Institutions. The Participating Institution consent form must follow the consent template as closely as possible  and should adhere to specifications outlined in the DF/HCC Guidance Document on 
Model Consent Language for PI -Initiated Multi -Center Protocols.  This document will be provided 
separately to each Participating Institution.  
 Participating Institutions are to send their version of the informed consent document and HIPAA 
83 
 
Protocol #: 13-559 
Version Date:   December 16, [ADDRESS_429547] also be submitted to the Coordinating 
Center after approval by [CONTACT_1036].  
 The Principal Inve stigator (PI) at each Participating Institution will identify the physician members of the 
study team who will be obtaining consent and signing the consent form for therapeutic protocols. Participating institutions must follow the DF/HCC requirement that o nly attending physicians obtain 
informed consent and re -consent to interventional trials (i.e. drug and/or device trials).   
 
3.[ADDRESS_429548] be on file with the Coordinating Center:  
• Approval letter of the Participating Institution's IRB  
• Copy of the Informed Consent Form approved by [CONTACT_57949]’s IRB  
• Participating IRB’s approval for all amendments  
 
It is the Participating Institution's responsibility to notify its I RB of protocol amendments.  Participating 
Institutions will have [ADDRESS_429549] ( HIPAA). Any information, related to the physical 
or mental health of an individual is called Protected Health Information (PHI). HIPAA outlines how and 
under what circumstances PHI can be used or disclosed.  
 In order for covered entities to use or disclose protected health information during the course of a study, the study participant must sign an Authorization.  This Authorization may or may not be separate from the informed consent document.  The C oordinating Center, with the approval from the DFCI IRB and if 
applicable NCI/CTEP, will provide a consent template, which covered entities (Participating Institutions) must use.   The DF/HCC Sponsor will use all efforts to limit its use of protected health information in its trials.  However, because of the nature of these trials, certain protected health information must be collected per NCI requirements. These are the primary reasons why DF/HCC has chosen to use Authorizations, signed 
by [CONTACT_89438], rather than limited data sets with data use agreements.  
 
3.6.1  DF/HCC Multi -Center Protocol Confidentiality  
84 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
 
All documents, investigative reports, or information relating to the participant are strictly confidential. Whenever reasonably feasible, any participant specific reports (i.e. Pathology Reports, MRI Reports, Operative Reports, etc.) submitted to the Coordinating Center must have the participant’s full name & social security number “blacked out” and the assigned DF/HCC QACT case number (as d escribed below) 
and DF/HCC protocol number written in (with the exception of the signed informed consent document). Participant initials may only be included or retained for cross verification of identification  
 
3.7 DF/HCC Multi- Center Protocol Registration Po licy 
 
3.7.[ADDRESS_429550] be registered with the DF/HCC QACT before receiving treatment.  Treatment may not be initiated until the Participating Institution receives a faxed or e -mailed copy of the participant’s 
registration confirmation memo from the Coordinating Center. Therapy must be initiated per protocol guidelines.  The DF/HCC Sponsor and DFCI IRB must be notified of any exceptions to this policy.  
3.7.3 Eligibility Exceptions  
 
CTEP specifically prohibits registration of a participant on any NCI Sponsored protocol that does not fully and completely meet all eligibility requirements. The DF/HCC QACT will make no e xceptions to 
the eligibility requirements for a protocol without DFCI IRB approval. The DF/HCC QACT requires 
each institution to fully comply with this requirement.  
 
3.7.4 Verification of Registration, Dose Levels, and Arm Designation  
 A registration confirmatio n memo for participants registered to DF/HCC Multi -Center Protocol  
will be emailed to the registering institution within one business day of the registration.  
Treatment may not be initiated until the site receives a faxed or e- mailed copy of the registrati on 
confirmation memo.  
 
3.8 DF/HCC Protocol Case Number  
 
Once eligibility has been established and the participant successfully registered, the participant is assigned a five digit protocol case number.  This number is unique to the participant on this trial and must 
be used for QACT CRF/eCRF completion and correspondence, and correspondence with the Coordinating Center.   
 
3.9 Protocol Deviations, Exceptions and Violations  
 Federal Regulations require an IRB to review proposed changes in a research activity to en sure that 
researchers do not initiate changes in approved research without IRB review and approval, except when necessary to eliminate apparent immediate hazards to the participant. DF/HCC requires all departures from the defined procedures set forth in th e IRB approved protocol  to be reported to the DF/HCC 
Sponsor, who in turn is responsible for reporting to the DFCI IRB. 
85 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
  
For reporting purposes, DF/HCC uses the terms “violation”, “deviation” and “exception” to describe 
derivations from a protocol. All Pa rticipating Institutions must adhere to these requirements for 
reporting to the DF/HCC Sponsor and will follow their institutional policy for reporting to their local IRB.  
 
3.9.1 Definitions  
 
Protocol Deviation : Any departure from the defined procedures set forth in the IRB -approved protocol 
which is prospectively approved  prior to its implementation.  
 
Protocol Exception :  Any protocol deviation that relates to the eligibility criteria, e.g.  
enrollment of a part icipant who does not meet all inclusion/exclusion criteria.  
   
Protocol Violation : Any protocol deviation that was not prospectively approved  by [CONTACT_254713].   
 
3.9.2  Reporting Procedures  
 
DF/HCC Sponsor:  is responsible for ensuring that clear documentation is available in the medical record 
and/or regulatory documents to describe all protocol exceptions, deviations and violations. The DF/HCC Sponsor will also be responsible for ensuring that all protocol violations/deviations are promptly reported 
per DFCI IRB guidelines.   
Participating Institutions : Protocol deviations require prospective approval from the DFCI IRB. The 
Participating Institution must submit the deviation request to the Coordinating Cente r who will then 
submit the deviation request to the DFCI IRB. Upon DFCI IRB approval the deviation is submitted to the Participating Institution IRB, per institutional policy. A copy of the Participating Institution’s IRB report and determination will be f orwarded to the Coordinating Center within [ADDRESS_429551] be sent to the Coordinating Center in a timely manner.  
 
Coordinating Center:   Upon receipt of the violation/deviation report from the  Participating Institution, the 
Coordinating Center will submit the report to the DF/HCC Sponsor for review. Subsequently, the Participating Institution’s IRB violation/deviation report will be submitted to the DFCI IRB for review per DFCI IRB reporting guidelines.  
 
3.10 Safety Assessments and Toxicity Monitoring  
 The study teams at all participating institutions are responsible for protecting the safety, rights and well -
being of study participants. Recording and reporting of adverse events that occur during the course of a 
study help ensure the continuing safety of study participants.  
 All participants receiving investigational agents and/or other protocol mandated treatment will be evaluated for safety.   The safety parameters include all laboratory tests and  hematological abnormalities, 
physical examination findings, and spontaneous reports of adverse events reported by [CONTACT_4317].  All toxicities encountered during the study will be evaluated according to the NCI criteria specified in the 
86 
 
Protocol #: 13-559 
Version Date:   December 16, [ADDRESS_429552] be reported immediately to the DF/HCC Sponsor via the 
Coordinating Center.  
 
Additional safety assessments and toxicity monitoring will be outlined in the protocol.  
 
3.10.1 Guidelines for Reporting Serious Adverse Events  
 
Guidelines for reporting Adverse Events (AEs) and Serious Adverse Events (SAEs) are detailed in 
protocol section 7.       
 
Participating Institutions must report the AEs to the DF/HCC Sponsor and the Coordinating Center 
following the DFCI IRB SAE Reporting Requirements.  
 The Coordinating Center will maintain documentation of all Participating Institution Adverse Event reports and be responsible for communicating to all participating investigators, any observations reportable under the DFCI IRB Reporting Requirements.  Participating Investigators will review any distributed AE reports, send a copy to their IRB according to their local IRB’s policies and procedures, and file a copy with their regulatory documents. 
 
 
3.10.2 Guidelines for Processing IND Safety Reports   
 
FDA regulations require sponsors of clinical studies to notify the FDA and all participating investigators 
of any adverse experience associated with the use of the investigational agent that is both serious and unexpected. The DF/HCC Sponsor will review  all IND Safety Reports and ensure that all IND Safety 
Reports are distributed to the Participating Institutions.  The Participating Institutions will review and submit to their IRB according to their institutional policies and procedures.  
  
   
3.11 Data Management  
 The DF/HCC QACT develops a set of electronic case report forms (eCRFs), for use with the protocol.  These forms are designed to collect data for each study. The DF/HCC QACT provides a web based training for eCRF users.  
   
3.11.1 Data Forms Review  
 
When data forms arrive at the DF/HCC QACT, they are reviewed for completeness, protocol treatment compliance, adverse events (toxicities) and response. Data submissions are monitored for timeliness and completeness of submission. Participating Institutions  are notified of their data submission delinquencies 
in accordance with the following:  
 
Incomplete or Questionable Data  
If study forms are received with missing or questionable data, the submitting institution will receive a written or electronic query fro m the DF/HCC QACT Data Analyst or study monitor.  Responses to all 
queries should be completed and submitted within 14 calendar days.  Responses may be returned on the written query or on an amended paper case report form, or in the case of electronic quer ies, within the 
electronic data capture (eDC) system. In the case of a written query for data submitted on a paper case report form,  the query must be attached to the specific data being re -submitted in response.   
87 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
 
Missing Forms  
If study forms are not sub mitted on schedule, the Participating Institution will receive a Missing Form 
Report from the Coordinating Center noting the missing forms.  These reports are compi[INVESTIGATOR_345894]/HCC QACT and distributed a minimum of four times a year.  
 
4.0 REQUISITIONING STUD Y DRUG  
  
The ordering of Palbociclib is specified in protocol Section 8.1.8.   For commercially available agents (i.e., aromatase inhibitors) , check with the local Director of Pharmacy 
and/or the Research Pharmacy to ensure that the agent is in stock. If t he agent is not stocked, ensure that 
the agent can be ordered once the protocol is approved by [CONTACT_1036].   Ensure that the pharmacy will be able to receive and store Palbociclib  according to state and federal 
requirements. The local IRB should be kept informed of who will supply the agent (i.e., [COMPANY_007] ) so that any 
regulatory responsibilities can be met in a timely fashion. 
  
5.0 MONITORING: QUALITY CONTROL  
 
The quality control process for a clinical trial requires verification of protocol compliance and data accuracy. 
As the Coordinating Center, the DF/HCC Lead Institution or designee with the aid of the QACT provides quality control oversight for the DF/HCC Multi- center Protocol. 
 
5.[ADDRESS_429553] source documents to the DF/HCC Lead Institution or designee for monitoring. Also, the Participating Institution may be subj ect to on -site 
monitoring conducted by [CONTACT_57954]/HCC Lead Institution or designee.  
 
The DF/HCC Lead Institution will implement on- site as well as virtual monitoring activities to ensure 
that Participating Institutions are complying with regulatory and protocol requirements, data quality, and subject safety. At a minimum, the DF/HCC Lead I nstitute, or designee, will monitor each participating 
site on an ongoing basis  while patients are receiving treatment. Should a Participating Institution be 
monitored once and then not accrue any additional patients or participant visits, then a second monitoring visit may not be necessary.  
Monitoring practices may include but are not limited to; source verification, review and analysis of the following: eligibility requirements of all participants, informed consent procedures, adverse events and all asso ciated documentation, study drug administration / treatment, regulatory records and site trial 
master files, protocol deviations,  pharmacy records, response assessments, and data management.  Additionally, regular and ongoing communication with Participat ing Institutions, will be accomplished 
by [CONTACT_345924]. The Lead Institution will keep in close touch with the Participating Institutions via email and phone. Source documents from Participating Institutions, will be collected at specif ic data points that support the primary and or secondary endpoints.  
 On-Site Monitoring: On -site monitoring will occur on an as -needed basis.  Participating Institutions 
will be required to provide access to participants’ complete medical record and source  documents for 
88 
 
Protocol #: 13-559 
Version Date:   December 16, [ADDRESS_429554] safety or the integrity of the study are found, or trends identified based on areas of need, additional monitoring 
visits may be scheduled. On site monitoring visits can be supplemented with virtual monitoring assessments, provided that the minimum monitoring frequencies are adhered to.  
 Virtual Monitoring: The Coordinating Center will reque st source documentation from Participating 
Institutions as needed to complete monitoring activities. Participating Institutions will be asked to forward de -identified copi[INVESTIGATOR_57912]’ medical record and source documents to the Coordinating 
Center to  aid in source documentation verification. 
  The Overall PI, or designee, will review all monitoring reports for on -site and virtual monitoring of 
Participating Institutions to ensure protocol compliance and ability to fulfill responsibilities of participa tion in the study. The Coordinating Center may increase the monitoring activities at 
Participating Institutions that are unable to comply with the protocol, DF/HCC requirements or federal and local regulations. Participating Institutions may also be subjec t to an audit as determined by [CONTACT_43898].  
 In addition to monitoring performed by [CONTACT_5081], DF/HCC QACT may monitor  data for 
timeliness of submission, completeness, and adherence to protocol requirements. The Lead Institution or designee and, if applicable, QACT Data Analysts assigned to the Protocol will perform the ongoing protocol data compliance monitoring with the support of the Participating Institution’s Coordinators, the 
Principal Investigators, and the Protocol Chair.  
 
5.2 Evaluation of Participating Institution Performance  
 
5.2.1 Monitoring Reports  
 
The DF/HCC Sponsor will review all monitoring reports for on -site and virtual monitoring of 
Participating Institutions to ensure protocol compliance and ability to fulfill responsibilities of 
participating in the study. The DF/HCC Sponsor may increase the monitoring activities at Participating Institutions that are unable to comply with the protocol, DF/HCC Sponsor requirements or federal and local regulations. Participating Institutions may also be subject to an audit as determined by [CONTACT_57954]/HCC 
Sponsor. 
 
5.2.2 Accrual of Eligible Participants:  
 
Prior to extending a protocol to an external site, the DF/HCC Sponsor will establish accrual requirements for each participating institution. Accrual will be monitored for each participating institution by [CONTACT_254478]/HCC Sponsor or designee. Sites that are not meeting their accrual expectations may be subject to 
termination.   
 A minimum of [ADDRESS_429555] of overseeing each site, a consideration of 5 per site/annually should be a minimum target for each site.   
89 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
 
 
6.0 AUDITING: QUALITY ASSURANCE  
 
Auditing is a method of Quality Assurance. I ts main focus is to measure whether standards and 
procedures were followed. Auditing is the systematic and independent examination of all trial related 
activities and documents.  Audits determine if evaluated activities were appropriately conducted and whether data was generated, recorded and analyzed, and accurately reported per the protocol, Standard 
Operating Procedures (SOPs), and the Code of Federal Regulations (CFR). 
 
6.1 NCI Sponsored Trials  
Not applicable.  
  
6.2 DF/HCC Sponsored Trials  
 
One on- site audit will be scheduled by [CONTACT_221854], assuming at least three participants have been treated 
on protocol at the site. Approximately 3- [ADDRESS_429556] participant safety  or the integrity of the study are found, more participant records 
may be audited.  
 
6.3 Participating Institution  
 
It is the Participating Institution’s responsibility to notify the Coordinating Center of all scheduled audit dates (internal or NCI) and re -audit dates (if applicable), which involve this protocol. All institutions will 
forward a copy of final audit and/or re -audit reports and corrective action plans (if applicable) to the 
Coordinating Center, within 12 weeks after the audit date.  
 
6.4 DF/HCC Sponso r and Coordinating Center  
 
The DF/HCC Sponsor will review all final audit reports and corrective action plans if applicable. The Coordinating Center, must forward these reports to the DF/HCC QACT per DF/HCC policy for review by [CONTACT_57954]/HCC Audit Committee.  Based upon the audit assessments the DF/HCC Audit Committee 
could accept or conditionally accept the audit rating and final report. Conditional approval could require the DF/HCC Sponsor to implement recommendations or require further follow -up.  For unacc eptable 
audits, the DF/HCC Audit Committee would forward the final audit report and corrective action plan to the DFCI IRB as applicable.  
 
6.[ADDRESS_429557] Performance  
 
The DF/HCC Sponsor, DFCI IRB and the NCI for CTEP trials, is charged with considering the totality of 
an institution’s performance in considering institutional participation in the protocol.  
 
6.5.[ADDRESS_429558] respond with a corrective action 
90 
 
Protocol #: 13-559 
Version Date:   December 16, [ADDRESS_429559] been corrected, as 
evidenced by [CONTACT_89445]. Participating Institutions that fail to demonstrate significant improvement will be considered by [CONTACT_57954]/HCC Sponsor for revocation of participation. 
  
91 
 
Protocol #: 13-559 
Version Date:   December 16, 2016  
APPENDIX H : PFIZER SAE FAX COVER SHEET  
 
 
 
92 
 
Protocol #: 13-559 
Version Date:  December 16, 2016  
APPENDIX I : QOL ASSESSMENT  
 
EORTC  QLQ -C30 (version  3) 
We are interested  in some  things  about  you and your health.  Please  answer  all of the questions  yourself  by [CONTACT_345925]. There  are no "right"  or "wrong"  answers.  The information that you provide  will remain  strictly  
confidential.  
Please fill in your initials:  ______  
Your  birthdate  (Day,  Month,  Year): _______  
Today's  date (Day,  Month,  Year):  _______ 
 
 Not at 
All A 
Little  Quite  
a Bit Very  
Much  
1. Do you have any trouble  doing  strenuous  activities,      
 like carrying  a heavy  shoppi[INVESTIGATOR_345895] a suitcase?  [ADDRESS_429560] any trouble  taking a long walk?  [ADDRESS_429561] any trouble  taking  a short  walk  outside  of the house?  1 2 3 4 
4. Do you need to stay in bed or a chair  during  the day?  1 2 3 4 
5. Do you need help with eating,  dressing,  washing      
 yourself  or using  the toilet?  [ADDRESS_429562] week:  Not at 
All A 
Little  Quite  
a Bit Very  
Much  
6. Were  you limited  in doing  either  your work or other  daily  activities?  1 2 3 4 
7. Were  you limited  in pursuing your hobbies  or other  
leisure time activities?   
1  
2  
3  
4 
8. Were  you short  of breath?  [ADDRESS_429563]  you had pain?  [ADDRESS_429564]?  [ADDRESS_429565]  you had trouble  sleepi[INVESTIGATOR_007]?  [ADDRESS_429566]  you felt weak?  [ADDRESS_429567]  you lacked  appetite?  [ADDRESS_429568]  you felt nauseated?  1 2 3 4 
93 
 
Protocol #:13 -559 
Version Date: April 1, [ADDRESS_429569]  you vomited?  [ADDRESS_429570]  you been constipated?  [ADDRESS_429571] week:  Not at 
All A 
Little  Quite  
a Bit Very  
Much  
17. Have  you had diarrhea?  1 2 3 4 
18. Were  you tired?  1 2 3 4 
19. Did pain interfere with your daily  activities?  [ADDRESS_429572]  you had difficulty  in concentrating  on things,      
 like reading  a newspaper  or watching  television?  1 2 3 4 
21. Did you feel tense?  1 2 3 4 
22. Did you worry?  1 2 3 4 
23. Did you feel irritable?  1 2 3 4 
24. Did you feel depressed?  [ADDRESS_429573]  you had difficulty  remembering  things?  1 2 3 4 
26. Has your physical  condition  or medical  treatment      
 interfered  with your family  life? 1 2 3 4 
27. Has your physical  condition or medical treatment  
interfered  with your social  activities?   
1  
2  
3  
4 
28. Has your physical  condition  or medical  treatment      
 caused  you financial  difficulties?  [ADDRESS_429574] week?  
 
[ADDRESS_429575] week?  
 
1 2 3 4 5 6 7 
Very  poor Excellent  
 
 
© Copyright 1995 EORTC Quality  of Life Group. All rights  reserved.  Version  3.0 
94 
 